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                                                    INTRODUCTION 
   Siddha  System is one of the ancient systems of medicine in the world . It is 
mainly based on three vital humours named Vali,Azhal and Iyyam. The inimitable of this 
system is efficacy of a single drug with various adjuvant evidenced for assortment of 
diseases. Siddha system not only deals with diseases , treatment , prevention , cure and 
also lifestyle. 
Athimetham (Hyperlipidemia) is one of the life style modification diseases in our 
country. Hyperlipidemia which is increased levels of lipids. Hyperlipidemia includes both 
hypercholestremia and hypertriglyceridemia. Although it does not show any symptoms it 
lay concrete for many diseases that cardiovascular diseases and stroke are very common 
due to atherosclerosis. Hyperlipidemia is one of the major risk factor for coronary heart 
disease (CHD) a major leading cause of mortality in developed countries, will soon 
become the pre-eminent health problem worldwide. 
Recent  epidemiological studies reveals that there is an increase in lipid levels 
globally. There is wide variation in the prevalence, awareness, and treatment of  
hyperlipidemia  between populations. According to WHO MONICA PROJECT the 
prevalence of hypercholesterolaemia  varied   across populations from 3% to 53% in men, 
and from 4% to 40% in women. Awareness of   hypercholesterolaemia varied from 1% to 
33% in men, and from 0% to 31% in women. In most   populations, over 50% of men and 
women on lipid-lowering drugs.1 
  The World Health Organization (WHO) reports that high cholesterol contributes 
to 56% of cases of coronary heart disease worldwide and causes more than 4 million 
deaths each year. In most parts of the world, the number of female deaths attributed to 
high cholesterol is slightly higher than the number of male deaths.2 
India is a developing country has been showing an increase in the incidence of 
hyperlipidemia, for the past few decades .In young adult Indian population the prevalence 
of dyslipidemia was observed to be higher in males than in females. Among participants 
who had a total Cholesterol (TC) concentration 200mg/dl, 38.7% were males and 23.3% 
were females. High density lipoprotein cholesterol (HDL-C) was abnormally low in 
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64.2% males and 33.8% in females. The increase of prevalence of hypercholesterolemia 
and  hypertriglyceridemia was more prominent in 31-40 age group than in  30 age group3 . 
Another epidemiological study in South India conducted by Sri  Ramachandra 
University, Chennai , mentioned that the prevalence of abnormal serum lipid levels was 
more prominent in the age group of 40-59 years in both the sexes. High levels of 
triglycerides were identified in 41.5% and very high levels in 1.2%, LDL- cholesterol 
levels were high in 32.9% and very high in 7.45%, and a higher total cholesterol levels 
were found in 25.35%. HDL- cholesterol levels were found to be low in 34.35%.4   
It is the right time for the measures to be taken for this disease. Many Siddha 
medicines have been indicated  for increased levels of lipids. Several indigenous plants 
have been claimed to possess hypolipidemic and hypocholesteremic properties that may 
be beneficial to reduce the risk of cardiovascular diseases. In Siddha text  Amukkara   
Kizhangu Chooranam is indicated for  Athimetham.5   
Athimetham is a one of the kabam related disorder. Amukkara   Kizhangu 
Chooranam   has kaippu suvai. It’s vibagam is kaarppu . It is mentioned in the siddha text 
that      , ,   
   .Many studies have been conducted in this herb. 
Flavanoids  of this herb showed  hypolipidemic  activity in  alloxan induced diabetic rats.6 
Another study   showed that  dietary herbal supplementation with Withania 
somnifera exhibited a significant reduction in levels of egg yolk total lipids, egg yolk 
cholesterol and egg yolk triglycerides of birds. 7  
Amukkara   Kizhangu Chooranam  has not been evaluated for hypolipidemic 
activity in diet induced hypercholestremic rat and clinical trial so far. This study is 
different from previous studies regarding adjuvant , dosage forms and methods.  
 
Hence the researcher has selected “Amukkara Kizhangu  Chooranam”to evaluate 
its Hypolipidemic activity and therapeutic effect in the management of Athimetham. 
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Aim: 
    To evaluate the safety and efficacy of  Amukkara Kizhangu Chooranam 
(Withania somnifera)  for   Hypolipidemic activity  in the management of Athimetham ( 
Hyperlipidemia). 
OBJECTIVE: 
Primary objective: 
 To evaluate the  Hypolipidemic activity of  Amukkara Kizhangu Chooranam 
(Withania somnifera)  in  preclinical studies. 
Secondary objective: 
Biochemical analysis. 
HPTLC. 
To evaluate the efficacy of  Amukkara Kizhangu Chooranam (Withania 
somnifera)  in clinical trial for Hypolipidemic activity in the management of   
Athimetham ( Hyperlipidemia). 
 
 
 
 
 
 
 
 
 
 
 
4 
 
MATERIALS AND METHODS 
STANDARD OPERATIVE PROCEDURE 
COLLECTION AND AUTHENTICATION OF RAW DRUG: 
Amukkara Kizhangu was procured from Raw drug store in Chennai and 
authenticated by competent authority in the department of Gunapadam , National Institute 
of Siddha, Chennai. 
PURIFICATION OF AMUKKARA5: 
Amukkara  Kizhangu was  boiled with milk and then dried in the shadow. 
METHOD OF MEDICINE PREPARATION: 
Purified  Amukkara Kizhangu was  pulverised by an electric grinder in to a fine 
powder and then it was  sieved by using a fine silk cloth (vasthra kaayam).The fine 
Powder was purified by pittavial method. Then it was  dried and ultrafiltered  by a cotton 
cloth and made in to fine powder again. The powder was  stored in a clean dry airtight 
glass bottle. 
LABELLING: 
 Name of the preparation :  Amukkara Kizhangu Chooranam   
 Quantity of the drug  :  Amukkara Kizhangu Chooranam [28g] 
 Dose    : 2 gm bd  
 Adjuvant or Vehicle  : Honey 
 Indication   : Athimetham  
 Date of manufacturing      :  The drug was prepared in 3 batches      
                                                                      13/3/12, 15/6/12,16/9/12 
            Expiry                          : 3 months. 
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Withania somnifera plant 
 
 
 
 
 
Withania somnifera raw drug 
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REVIEW OF LITERATURE 
SIDDHA ASPECT 
«ÓìÌÃ¡ì¸¢ÆíÌ -AMUKKURA-KIZHANGU.5
 
Withania somnifera(Linn) 
 
    §ÅÚ¦ÀÂ÷¸û : 
            «Óì¸¢Ã¢ 
            «ÓìÌÃÅ¢ 
            «ÓìÌÃ× 
            «Óì¸¢Éí¸¢ÆíÌ 
            «ÍÅ¸ó¾¢ 
            «ÍÅõ 
            Õ ¢î¦ºÅ¢ 
            ¸¢Êî¦ºÅ¢ 
            ÅÃ¡¸¸÷½¢ 
ÀÂýÀÎõ ¯ÚôÒ : ¨Ä,Å¢¨¾,§Å÷(¸¢ÆíÌ) 
Í¨Å   : ¨¸ôÒ  
Å£Ã¢Âõ   : ¦ÅôÀõ 
À¢Ã¢×    : ¸¡÷ôÒ. 
¦ºö¨¸: 
¨Ä      :  ¦ÅôÀ¸üÈ¢. 
¸¡ö    :   º¢Ú¿£÷ô¦ÀÕì¸¢ 
  ¸¢ÆíÌ  :    ¯¼ü§ÈüÈ¢ 
            ¬ñ¨Á¦ÀÕì¸¢ 
             Å£ì¸ÓÕì¸¢ 
             ¯ÃÁ¡ì¸¢ 
             º¢Ú¿£÷ô¦ÀÕì¸¢ 
             ¯Èì¸Óñ¼¡ì¸¢ 
             ¯¼ø¦ÅôÀ¸üÈ¢ 
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Ì½õ:  
ì¸¢ÆíÌ ¸Âõ Å ¢ìÌð¼í¸û ¸ÃôÀ¡ý, ÍÃõ, Å£ì¸õ ¨Å¸¨  
§À¡ìÌõ. Àº¢ò¾£¨ÂÔñ¼¡ìÌõ. 
¦À¡ÐÌ½õ: 
           ¦¸¡ïºó ÐÅ÷ôÀ¡í ¦¸¡ÊÂ¸Âõ Ý¨ÄÂÃ¢ 
           Á¢ïÍ¸Ãô À¡ýÀ¡ñÎ ¦ÅôÒ¾ôÒ- Å¢ïº¢ 
           ÓÍ×Ú §¾¡¼Óõ§À¡ §Á¡¸õ«É Öñ¼¡õ 
           «ÍÅ¸ó ¾¢ì¦¸ý üÈ¢ 
           
........................................... 
..........................§¸¡Ä 
¿Ì¼ ¦ÅÕñÎ¾¢Ã ¿¡ðÎ¨Å§Âý §Á¨Ä 
¿Ì¼ ¦ÅÕñÎÚÅ¡ú ¿¡û 
 
«Óì¸¢É¡í¸¢ÆíÌ,¦À¡Ê ¦¿ö Ó¾Ä¢ÂÉ ¦ºöÐ 
ÀÂýÀÎò¾¢É¡ø,¯Ú¾¢,«ÆÌ ¿£ñ¼ ¬Ôû Ó¾Ä¢Â¨Å¸û ¯ñ¼¡Ìõ. 
§Áø âîÍ: 
«Óì¸¢É¡í¸¢ÆíÌô Àî¨ºÂ¡öì ¦¸¡ñÎÅóÐ ÀÍÅ¢ý ¿£÷ Å¢ð¼¨ÃòÐ 
¦¸¡¾¢ì¸¨ÅòÐ, (¸Æ¨Ä)¸¢Ãó¾¢, (¸ØòÐì ¸Æ¨Ä)¸ñ¼Á¡¨Ä,Å£ì¸õ, ÎôÒÅÄ¢ 
¨Å¸ÙìÌô ÀüÈ¢¼, ¨Å¸û Å¢ÄÌõ. 
¨¾î ÍìÌ¼ý §º÷òÐ ¦Åó¿£÷Å¢ð¼¨ÃòÐ, Å£ì¸í¸ÙìÌô §À¡¼ì 
¸¨ÃÔõ. 
¸¢ÆíÌ «øÄÐ ¨Ä¨Â «¨ÃòÐ §Á¸ì¸ðÊ, §¿¡Ô¼ýÜÊÂ Å£ì¸õ, 
Òñ ¨Å¸ðÌô âºÄ¡õ 
                    
ÌÊ¿£÷: 
¸¡ø Ó¾ø «¨Ã ÀÄõ ±¨¼Ôû  ¨Ä¨Â Å¢¾¢ôÀÊ ÌÊ¿£÷ ¦ºöÐ 
¦¸¡Îì¸î ÍÃó¾½¢Ôõ, «øÄÐ °Èø ¿£÷ ¦ºöÐí ¦¸¡Îì¸Ä¡õ  
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  «ÓìÌÃ¡ì ¦À¡Ê: 
 ¸¢Æí¨¸ô À¡Ä¢ø §Å¸¨ÅòÐ  «ÄõÀ¢ ,¯Ä÷ò¾¢,¦À¡Ê 
¦ºöÐ ´Õ §Å¨ ìÌ 2 Ó¾ø 4 ¸¢Ã¡õ Å¨Ã §¾É¢ü ¸ÄóÐ 
¦¸¡Îì¸,Å ¢ ³Âõ ÅüÈ¡ø À¢Èó¾ §¿¡ö¸û, 
Å£ì¸õ,Àº¢Â¢ý¨Á, ¯¼ø ÀÕÁý ¨Å¸û §À¡õ. 
 
 ¦¿öÔ¼ý ¸ÄóÐ ¦¸¡Îì¸,µöîºø ¦ÀÕãîÍ  §À¡õ. 
¯¼üÌ Åý¨Á¾Õõ,Å¢óÐ¨Åô ¦ÀÕìÌõ. 
 
 «Óì¸¢Ã¡ì ¸¢ÆíÌô  ¦À¡Ê 1 ÀíÌõ ¸ü¸ñÎ 3 ÀíÌõ 
§º÷òÐ §Å¨ ìÌ 4 ¸¢Ã¡õ ¸¡¨Ä Á¡¨Ä  ¯ð¦¸¡ñÎ, 
«¨Ã «øÄÐ µ÷ ¬Æ¡ìÌô ÀÍÅ¢ý À¡ø º¡ôÀ¢ðÎÅÃ, 
¿ÃõÒò ¾ ÷îº¢ ¬¸¢Â ¨Å¸û ¿£íÌõ ,¯¼ø Åý¨Á 
¦ÀÕõ, «ÆÌ ¾Õõ. 
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BOTANICAL  ASPECT 
Botanical Classification8 
 Kingdom :    Plantae. 
 Division :    Angiospermae.  
 Class  :    Dicotiledoneae.  
 Order  :    Tubiflorae. 
 Family  :    Solanaceae. 
 Genus  :   withania  
 Species :   somnifera .  
Common Name9: 
 English  -     Winter cherry   
Latin    -     Withania somnifera  
Sanskrit   -      Ashwagandha 
Hindi   -     Asgandh   
Tamil   -      Asuragandhi, Amukkira 
Kannada  -     Keramaddinagaddi  
Telgu   -     Vajigandha, Pennerugadda   
Malayalam  -      Amukkuram, Trittavu.  
Marathi  -      Askandha  
Marathi  -     Asgundh, Kanchuki, Askandha 
Bengali  -      Ashvagandh 
Punjabi  -      Asgand 
Urdu     -      Asgandanagaori 
Ashwagandha is a small, branched, perennial woody shrub that grows usually 
about 2 feet in height and is naturally found in diverse areas ranging from Africa, the 
Mediterranean and East into India. Because of its wide range, there is considerable 
morphological and chemo typical variations in terms of local species10.  
Flower: 
 Ashwagandha has sessile, axillary, greenish or lurid yellow flowers. They are 
hermaphrodite (has both male and female organs). 
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Fruit: 
 The fruit is Orange-red berry, smooth, oblong, rounded or somewhat produced at 
base. The fruit is harvested in the late fall and the bright yellow seeds are dried for 
planting in the following spring. 
Roots : 
 It has a more or less tuberous root 
Seed:  
 The seeds are yellow and scurfy.  
Plant Constituents of Withania 11 
Contains:  
 Alkaloids  
 Anaferine  
 Isopelietierine  
 Saponins  
 Sitoindoside VII  
 Sitoindoside VIII  
 Steroidal Lactones  
 Withaferins  
 Withanolides  
 Sitoindoside IX  
 Sitoindoside X  
 Iron  
Action:  
 Adaptogen [normalizes physical functioning depending on what the individual 
needs, e.g. it will lower high blood pressure, but raise low blood pressure]  
 Anti-inflammatory [an agent to ease inflammation]  
 Anti-tumor (in high doses)  
 Nervine [an agent that has a calming or soothing effect on the nerves, any agent 
that acts on the nervous system to restore the nerves to their natural state]  
 Sedative [a soothing agent that reduces nervousness, distress or irritation]  
 Tonic [an agent that tones, strengthens and invigorates organs or the entire 
organism giving a feeling of well-being].  
12 
 
JOURNAL REVIEW OF   WITHANIA SOMNIFERA 
The major biochemical constituents of Withania somnifera  root are steroidal 
alkaloids and steroidal lactonesin a class of constituents called withanolides.1 
A series of animal studies show Withania somnifera  to have profound effects on 
the hematopoietic system, acting as an   chemoprotective agent2..3 
The immunomodulatory activities11 of  i.e. extracts from Withania somnifera (L.) 
Dunal (Solanaceae), namely WST and WS2, were studied in mice for immune 
inflammation, active paw anaphylaxis and delayed type hypersensitivity (DTH). 
Immunomodulatory effect was assessed in  IgE-mediated anaphylaxis as reduction of 
ovalbumin-induced paw edema, in animals treated with WS2 at doses of 150 and 300 
mg/kg, and the results were compared with the standard drug disodium chromoglycate. In 
the DTH model, the modulatory effect was assessed as potentiation or suppression of the 
reaction, revealing an increase or decrease in mean foot pad thickness, respectively. 
Potentiation of the DTH reaction was observed in animals treated with cyclophosphamide 
at a dose of 20 mg/kg, WST at a dose of 1000 mg/kg and WS2 at a dose of 300 mg/kg. 
On the other hand, cyclophosphamide-induced potentiation of DTH reaction was 
suppressed in animals treated with WST and WS2. A significant increase in white blood 
cell counts and platelet counts was observed in animals treated with WST. A protective 
effect in cyclophosphamide-induced myelosuppression was observed in animals treated 
with WST and WS2, revealing a significant increase in white blood cell counts and 
platelet counts. Cyclophosphamide-induced immunosuppression was counteracted by 
treatment with WS2, revealing significant increase in hemagglutinating antibody 
responses and hemolytic antibody responses towards sheep red blood cells. 
In a mouse study, administration of a powdered root extract from Withania 
somnifera  was found to enhance total whiteblood cell count. In addition, this extract 
inhibited delayed-type hypersensitivity reactions and enhanced phagocytic activity of 
macrophages when compared to a control group.4 
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Nitric oxide has been determined to have a significant effect on macrophage 
cytotoxicity against microorganisms and tumor cells.  Withania somnifera  increased NO 
production in mouse macrophages in a concentration-dependent manner. This effect was 
attributed to increased production of inducible nitric oxide synthase, an enzyme generated 
in response to inflammatory mediators and known to inhibit the growth of many 
pathogens.5 
Withania somnifera  exhibited stimulatory effects,both in vitro and in vivo, on the 
generation of cytotoxic T lymphocytes, and demonstrated the potential to reduce tumor 
growth.6 
The chemopreventive effect was demonstrated in a study of Withania somnifera  
root extract on induced skin cancer in Swiss albino mice given Withania somnifera   
before and during exposure to the skin cancer causing agent 7,12-
dimethylbenz[a]anthracene. A significant decrease in incidence and average number of 
skin lesions was demonstrated compared to the control group. Additionally, levels of 
reduced glutathione, superoxide dismutase, catalase,and glutathione peroxidase in the 
exposed tissue returned to near normal values following administration of the extract. The 
chemopreventive activity is thought to be due in part to the antioxidant free radical 
scavenging activity of the extract.7 
An in vitro study showed withanolides from Withania somnifera  inhibited growth 
in human breast, central nervous system, lung, and colon cancer cell lines comparable to 
doxorubicin. Withaferin A more effectively inhibited growth of breast and colon cancer 
cell lines than did doxoorubicin. These results suggest Withania somnifera  extracts may 
prevent or inhibit tumor growth in cancer patients, and suggest a potential for 
development of new chemotherapeutic agents. Withania somnifera  extracts may prevent 
or inhibit tumor growth in cancer patients, and suggest a potential for development of 
new chemotherapeutic agents.8. 
 In an animal study assessing the anxiolytic and antidepressive actions of Withania 
somnifera  compared to commonly prescribed pharmaceuticals, an extract of the root was 
administered orally to rats once daily for five days. The results were compared to a group 
administered the benzodiazepine lorazepam for anxiolytic activity, and the tricyclic 
antidepressant imipramine for antidepressant investigation. Both the Withania somnifera  
14 
 
group and the lorazepam group demonstrated reduced brain levels of a marker of clinical 
anxiety. Withania somnifera  also exhibited an antidepressant effect comparable to that 
induced by imipramine in the forced swim-induced “behavioral despair” and“learned 
helplessness” tests9. 
Flavonoids were determined in the extracts of W. somnifera root (WSREt) and 
leaf (WSLEt). The amounts of total flavonoids found in WSREt and WSLEt were 530 
and 520 mg/100 g dry weight (DW), respectively. Hypoglycaemic and hypolipidaemic 
effects of WSREt and WSLEt were also investigated in alloxan-induced diabetic rats. 
WSREt and WSLEt and the standard drug glibenclamide were orally administered daily 
to diabetic rats for eight weeks. After the treatment period, urine sugar, blood glucose, 
haemoglobin (Hb), glycosylated haemoglobin (HbA1C), liver glycogen, serum and 
tissues lipids, serum and tissues proteins, liver glucose-6-phosphatase (G6P) and serum 
enzymes like aspartate transaminase (AST), alanine transaminase (ALT), acid 
phosphatase (ACP) and alkaline phosphatase (ALP) levels were determined. The levels of 
urine sugar, blood glucose, HbA1C, G6P, AST, ALT, ACP, ALP, serum lipids except 
high density lipoprotein-bound cholesterol (HDL-c) and tissues like liver, kidney and 
heart lipids were significantly (p < 0.05) increased, however Hb, total protein, albumin, 
albumin:globulin (A:G) ratio, tissues protein and glycogen were significantly (p < 0.05) 
decreased in alloxan-induced diabetic rats. Treatment of the diabetic rats with WSREt, 
WSLEt and glibenclamide restored the changes of the above parameters to their normal 
level after eight weeks of treatment, indicating that WSREt and WSLEt possess 
hypoglycaemic and hypolipidaemic activities in alloxan-induced diabetes mellitus (DM) 
rats10. 
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   PHYSICAL PROPERTIES 
The physical properties for  the drug Amukkara  Kizhangu Chooranam was 
carried out in Sri Ramachandra University, Chennai. 
pH at 10% of aqueous solution: 
Five grams of the sample was weighed accurately and placed in clear 100 ml 
beaker. Then 50 ml of distilled water was added to it and dissolved well. After 30 minutes 
it was then applied in to pH meter at standard buffer solution of 4.0,7.0,9.2(trial drug 1 
table 2) 
Ash Values: 
The Ash values are a measure of the inorganic constituents present in the raw 
drug.  A high ash content explains its unsuitable nature to be used as a drug (trial  
drug table 2) 
Total Ash: 
A little of extract was taken in a silica crucible previously ignited, cooled and 
weighed. It was incinerated by gradually increasing the heat not exceeding dull red heat 
(450°C) until free from carbon, cooled and weighed. The percentage of ash 
was calculated with reference to air- dried drug. The procedure was repeated to get the 
constant weight.  (trial drug  1table 2) 
Water soluble ash: 
The total ash was boiled with 25 ml water and filtered through ash less filter paper 
(Whatmann4.1). It was followed by washing with hot  water .The  filter paper  was dried  
and ignited in the silica crucible, cooled and the water insoluble ash was weighed. The 
water-soluble ash can be calculated by subtracting the water insoluble ash from the total 
ash. (trial drug1table2) 
Acid insoluble ash: 
The total ash obtained was boiled for 5 minutes with 25 ml of (10% w/v) dilute 
hydrochloric acid and filtering through ash less filter paper (Whatmann 4.1).  The filter 
paper was ignited in the silica crucible, cooled and insoluble ash was weighed. ( trial drug 
1 table 2) 
16 
 
HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY 
HPTLC Fingerprint - RH1 
 
HPTLC for the drug Amukkara  Kizhangu Chooranam was carried out in Sri 
Ramachandra University, Chennai. 
Sample Preparation 
100 mg of extract was weighed and dissolved in 70% methanol to get a 
concentration of 10mg/ml concentration this is then used for injection.  
Chromatographic Conditions 
SampleName    :  AKC powder 
Sample-ID                    :           110 
Stationary Phase                     :  Silica gel 60 F 254   
Mobile Phase                           :  chloroform: methanol (9:1) 
Scanning Wavelength              :  404 nm 
Applied volume                       :  10µl 
Development mode                 :  Ascending mode 
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Significance of HPTLC fingerprinting in Standardisation 
Standardisation of traditional medicine has become mandatory in the present 
national and international scientific scenario, as they have to stand competing with 
stringent regulatory methods and also clinically. HPTLC is one of the versatile 
chromatographic methods presently available for the rapid analysis of herbal drugs due to 
several reasons. Firstly the time required for the demonstration of the most of the 
characteristic constituents of a drug is very quick and short. Secondly, in addition to 
qualitative detection, HPTLC also provides semi-quantitative information on the major 
active constituents of a drug, thus enabling an assessment of drug quality. Thirdly the 
fingerprint obtained is suitable for monitoring the identity and purity of drugs and for 
detecting adulteration and substitution. Hence in order to check the identity, purity and 
standardise the quantity of active principles in the herbal extracts a HPTLC has been 
obtained.       
The distribution of phyto-constituents in a plant depends on various factors such 
as soil, time of collection period of storage, etc. So, it is necessary to standardize the 
extract being used for pharmacological studies. HPTLC serves as a convenient tool for 
finding out the distribution pattern of phyto constituents which is unique to each plant. 
The HPTLC finger-printing profile establishes the identity and purity of the raw drug 
being used. It helps in the authentification of the plant material.  
Chromatographic Conditions 
The finger printing has been done using the following chromatographic 
conditions. Chromatography was performed on a10x10 cm pre activated HPTLC silica 
gel 60F 254 plate. Samples were applied to the plate as 6mm wide band with an 
automatic TLC applicator Linomat 5 with N2 flow (CAMAG, Switzerland), 8mm from 
the bottom. Densitometric scanning was performed on CAMAG scanner III.The plates 
were pre-washed by methanol and activated at 600 C for 5 minutes prior to 
chromatography. The slit dimension was kept at 5 minutes x 0.45 minutes and 20 minutes 
scanning speed was employed. The mobile phase was chosen after running each plant in 
different mobile phases of varying polarity (Toluene, Toluene: Ethyl acetate and Ethyl 
acetate: Methanol) and 10 ml of mobile phase was used per chromatography. Linear 
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ascending development was carried out in 20 cm x 10-em twin glass chamber saturated 
with the mobile phase.  
Chromatographic Analysis 
The hydro alcoholic extracts of the plants have been prepared at a concentration of 
10 mg/10 ml in alcohol and were spotted using CAMAG Linomat 5 applicator. The 
method was optimized by selecting appropriate mobile phase for respective plant extracts 
and developed in a twin trough chamber, 20 x 10 cm at 25°C. The plates were dried by 
hair dryer. The developed plates were scanned at appropriate wavelength using CAMAG 
TLC scanner 3 and photo-documented using CAMAG REPROSTAR 3( graph 1-9). 
Inferences: 
HPTLC fingerprint of RH -1 shows four peaks at Rf values 0.25, 0.31, 0.41 & 
0.95.  The peak correspond to the Rf value 0.31 has maximum peak area of 7256.5. At 
this stage it is difficult to confirm the individual components present in the extract, but 
from our lab experience on phytochemical analysis, we suggest that the major peaks 
found in the fingerprint may be acidic glycosides / resins. Since, in the present 
chromatographic conditions, the above mentioned components will be eluted easy.  
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Fingerprint chromatogram of RH -1 at 404nm 
Amukkara kizhangu Chooranam 
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BIOCHEMICAL  ANALYSIS    OF AMUKKARA KIZHANGU 
CHOORANAM 
 The biochemical analysis of the Amukkara Kizhangu Chooranam was carried out 
in the Biochemistry lab, NIS. 
S.No EXPERIMENT OBSERVATION INFERENCE 
1.         Appearance of sample Light yellow in 
colour 
 
2. Solubility: 
a. A little(500mg) of the sample was 
shaken well with distilled water. 
b. A little(500mg) of the sample was 
shaken well with con. HCl/Con. H2So4 
Sparingly soluble 
 
 
Absence of 
Silicate 
3. Action of Heat: 
   A small amount(500mg) of the sample 
was taken in a dry test tube and heated 
gartly at first and then strong. 
 
 No white fumes 
evolved  
 
 
Absence of 
Carbonate 
 
4. Flame Test: 
  A small amount(500mg) of the sample was 
made into a paste with con. HCl in a watch 
glass and introduced into non-luminous part 
of the Bunsen flame. 
 No Bluish green 
flame appeared. 
Absence of 
Copper 
5. Ash Test: 
   A filter paper was soaked into a mixture 
of sample and dil. cobalt nitrate solution and 
introduced into the Bunsen flame and 
ignited. 
No yellow colour 
flame appeared. 
Absence of 
sodium 
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Preparation of Extract: 
5gm of Amukkura Kizhangu Choornam[Withania sonifera.] was weighed 
accurately and placed in a 250ml clean beaker and added with 50ml of distilled water. 
Then it was boiled well for about 10 minutes. Then it was cooled and filtered in a 100ml 
volumetric flask and made up to 100ml with distilled water. 
S.No EXPERIMENT OBSERVATION INFERENCE 
 I.Test For Acid Radicals   
1.  Test For Sulphate: 
a. 2ml of the above prepared extract 
was taken in a test tube to this added 2ml 
of 4% dil ammonium oxalate solution 
b. 2ml of the above prepared extracts 
was added with 2ml of dil-HCl was added 
until the effervescence ceases off. Then 
2ml of dil.Barium chloride solution was 
added. 
No cloudy 
appearance. 
 
 
   Absence  
of Sulphate 
 
 
 
2. Test For Chloride: 
  2ml of the above prepared extract was 
added with dil. HCl till the effervescence 
ceases. Then 2ml of dil.silver nitrate 
solution was added. 
No cloudy 
appearance. 
  Absence  
of Chloride 
3. Test For Phosphate: 
  2ml of the extract was treated with 2ml 
of dil.ammonium molybdate solution and 
2ml of con.HNo3. 
 No Yellow 
appearance present 
   Absence  
of Phosphate 
4 
.  
Test For Carbonate: 
    2ml of the extract was treated with 2ml 
dil. Magnesium sulphate solution 
No Cloudy 
appearance. 
  Absence  
of carbonate 
5. Test For Nitrate: 
  1gm of the substance was heated with 
copper turning and concentrated H2So4 
and viewed the test tube vertically down. 
 
No Brown gas 
evolved. 
 
   Absence  
of Nitrate 
6. Test For Sulphide: 
  1gm of the substance was treated with 
2ml of con. HCL 
No Rotten Egg 
Smelling gas. 
   Absence  
of Sulphide 
7. Test For Fluoride & Oxalate: 
  2ml of extract was added with 2ml of dil. 
Acetic acid and 2ml dil.calcium chloride 
solution and heated. 
No Cloudy 
appearance 
      Absence  
of fluoride 
and oxalate 
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8. Test For Nitrite: 
  3drops of the extract was placed on a 
filter paper, on that-2 drops of dil.acetic 
acid and 2 drops of dil.Benzidine solution 
was placed. 
No Characteristic 
changes 
   Absence  
of Nitrite 
9. Test For Borate: 
  2 Pinches(50mg) of the substance was 
made into paste by using dil.sulphuric 
acid and alcohol (95%) and introduced 
into the blue flame. 
No Bluish green 
colour flame. 
   Absence  
of borate 
 II. Test For Basic Radicals   
1. Test For Lead: 
        2ml of the extract was added with 
2ml of dil.potassium iodine solution. 
No yellow 
Precipitate 
obtained. 
Absence of 
Lead 
2. Test For Copper: 
a. One pinch(50mg) of substance 
was made into paste with con. HClin a 
watch glass and introduced into the non-
luminuous part of the flame. 
No Blue colour 
flame 
No Blue colour 
precipitate formed. 
 
  Absence  
of copper 
 
 
3. Test For Aluminium: 
  To the 2ml of extract, dil.sodium 
hydroxide was added in 5 drops to excess. 
NoYellow colour 
appeared. 
   Absence   
of aluminium 
4. Test For Iron: 
a. To the 2ml of extract,2ml of 
dil.ammonium solution was added. 
b. To the 2ml of extract 2ml  
thiocyanate solution and 2ml  of con 
HNo3 was added 
 
blood red colour 
appeared. 
 
 
 
presence of 
Iron 
 
 
5. Test For Zinc:  
      To 2ml of the extract, dil.sodium 
hydroxide solution was added in 5 drops 
to excess and dil.ammonium chloride was 
added. 
 
No White 
precipitate was  
formed 
 
Absence of 
Zinc 
6. Test For Calcium:  
      2ml of the extract was added with 2ml 
of 4% dil.ammonium oxalate solution  
 No Cloudy 
appearance and 
white precipitate 
was obtained 
 
   Absence  
of calcium 
7. Test For Magnesium:  
         To 2ml of extract dil.sodium 
hydroxide solution was added in drops to 
excess. 
 
No White 
precipitate was  
obtained 
 
   Absence  
of 
Magnesium 
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8. Test For Ammonium: 
  To 2ml of extract 1 ml of Nessler's 
reagent and excess of dil.sodium 
hydroxide solution are added. 
 
  No Brown colour 
appeared 
 
     Absence  
 of 
ammonium 
9. Test For Potassium:  
   A pinch(25mg) of substance was treated 
of with 2ml of dil.sodium nitrite solution 
and then treated with 2ml of dil.cobalt 
nitrate in 30% dil.glacial acetic acid. 
 
No Yellowish 
precipitate was 
obtained. 
 
   Absence  
of Potassium 
10. Test For Sodium: 
    2 pinches(50mg) of the substance was 
made into paste by using HCl and 
introduced into the blue flame of Bunsen 
burner. 
 yellow colour 
flame appeared 
    Presence  
of sodium 
11. Test For Mercury:  
   2ml of the extract was treated with 2ml 
of dil.sodium hydroxide solution.  
 
No yellow 
precipitate was 
obtained 
   Absence  
of mercury 
12. Test For Arsenic:  
   2ml of the extract was treated with 2ml 
of dil.sodium hydroxide solution. 
 
No brownwish red 
precipitate was 
obtained 
 
    Absence  
of arsenic 
 III. Miscellaneous   
1.
  
Test For Starch:  
  2ml of extract was treated with weak 
dil.iodine solution  
 
No  blue colour 
developed 
 
      absence  
of starch 
2.
  
Test For Reducing Sugar:  
    5ml of Benedict's qualitative solution 
was taken in a test tube and allowed to 
boil for 2 minutes and added 8 to 10 drops 
of the extract and again boil it for 2 
minutes. The colour changes are noted. 
 
 
Brick red colour 
not developed 
 
   Absence of  
reducing 
sugar 
3.
  
Test For The Alkaloids: 
a) 2ml of the extract was treated with  2ml 
of dil.potassium iodide solution. 
b)  2ml of the extract was treated with  
2ml of dil.picric acid. 
c)  2ml of the extract was treated with 2ml 
of dil.phosphotungstic acid. 
 
 
. 
  
Yellow colour 
developed 
 
- 
 
   Presence  
of Alkaloid 
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4.
  
Test For Tannic Acid:  
  2ml of extract was treated with 2ml of 
dil.ferric chloride solution  
  black precipitate 
was obtained 
    Absence  
of Tannic acid 
5.
  
Test For Unsaturated Compound: 
  To the 2ml of extract 2ml of 
dil.Potassium permanganate solution was 
added.  
 
Potassium 
permanganate was 
not decolourised 
 
     Absence  
of unsaturated 
compound  
6.
  
Test For Amino Acid: 
    2 drops of the extract was placed on a 
filter paper and dried well. 20ml of  
Biurette reagent was added. 
 
 No Violet colour 
developed 
 
   Absence  
of amino 
acids 
7. Test For Type Of Compound: 
    2ml of the extract was treated with 2 ml 
of dil.ferric chloride solution.  
No green colour 
developed 
 
 
No red colour 
developed 
 
 
 
No violet colour 
developed 
 
No blue colour 
developed 
Absence of 
oxy quinole 
pinephrine 
and pyro 
catechol 
Anti pyrine, 
Aliphatic 
amino acids 
and meconic  
acid are 
absent  
Apomorphine 
salicylate and 
Resorcinol 
are absent 
Morphine, 
Phenol cresol 
and hydro 
uinone are 
absent 
 
 
 
 
 
 
 
 
 
 
 
25 
 
ACUTE AND SUB ACUTE TOXICITY STUDY ON AMUKKARA 
KIZHANGU    CHOORANAM IN RODENTS 
Animals:   
 Mice of either sex weighing 25-30g and rats weighing 210-240g were obtained 
from the animal house of Vels University. The animals were used with the approval of the 
Institute animal ethics committee and obtained from Vels University, Chennai. They were 
fed with a balanced standard pellet diet and maintained under standard laboratory 
conditions, providing 24-280C temperature, standard light cycle (12 h light, 12 h dark) 
and water ad libitum. Animals were kept in cages with raised floors of wide mesh to 
prevent coprophagy. Animal welfare guidelines were observed during the maintenance 
period and experimentation. The rats were randomly assigned to control and different 
treatment groups, six animals per group. (Approval number: 
XIII/VELS/PCOL/36/2000/CPCSEA/IAEC/08.08.2012). The animals were acclimatized 
for one week under laboratory conditions.  
ACUTE TOXICITY STUDY-OECD 425 GUIDELINES 
 Acute oral toxicity test for the Amukkara Kizhangu Chooranam was carried out as 
per OECD Guidelines 425. As with other sequential test designs, care was taken to ensure 
that animals are available in the appropriate size and age range for the entire study. The 
test substance is administered in a single dose by gavage using a stomach tube or a 
suitable intubation cannula. The fasted body weight of each animal is determined and the 
dose is calculated according to the body weight. After the substance has been 
administered, food was withheld for  further 2 hours in mice. The animals were observed 
continuously for the first 4 h and then each hour for the next 24 h and at 6 hourly intervals 
for the following 48 h after administering of the test drug, to observe any death or 
changes in general behaviour and other physiological activities. Single animals are dosed 
in sequence usually at 48 h intervals. However, the time interval between dosing is 
determined by the onset, duration, and severity of toxic signs. Treatment of an animal at 
the next dose was delayed until one is confident of survival of the previously dosed 
animal.  
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Observation of toxicity signs: General behavior, respiratory pattern, cardiovascular 
signs, motor activities, reflexes, change in skin and fur, mortality and the body weight 
changes were monitored daily. The time of onset, intensity, and duration of these signs, if 
any, was recorded.  
SUB-ACUTE TOXICITY  
 In a 28-days sub acute toxicity study, twenty four either sex rats were divided into 
four groups of 6 rats each. Group I that served as normal control was administered with 
distilled water (p.o.) while groups II, III and IV were administered daily with the 
Amukkara Kizhangu Chooranam (p.o.) for 28 days at a dose of 100, 200 and 400g/kg 
respectively. The animals were then observed daily for gross behavioural changes and 
any other signs of subacute toxicity. The weight of each rat was recorded on day 0 and 
weekly throughout the course of the study, food and water consumption per rat was 
calculated. At the end of the 28 days they were fasted overnight, each animal was 
anaesthetized with diethylether, following which they were then dissected and blood 
samples were obtained by cardiac puncture into heparinised tubes. The blood sample 
collected from each rat was centrifuged with 3000 X g at 4oC for 10 min to separate the 
serum and used for the biochemical assays.  
Hematological and blood biochemical analyses:  
 At the end of the study, all animals were kept fasted for 16-18 h and then 
anesthetized with anesthetic ether on the 28th day. Blood samples for hematological and 
blood chemical analysis were taken from retro orbital vein. Heparinized blood samples 
were taken for determining complete blood count (white blood cell count, differential 
white blood cell count, platelet count, red blood cell count, hematocrit, and hemoglobin) 
by semi automated hematology analyzer. The serum from non-heparinized blood was 
carefully collected for blood chemistry and enzyme analysis (glucose, blood urea nitrogen 
(BUN), creatinine, total protein, albumin, total and direct bilirubins, serum glutamate-
oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), and 
alkaline phosphatase (ALP)) were automatically determined using autoanalyzer. 
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Necropsy:  
 All rats were sacrificed after the blood collection. The positions, shapes, sizes and 
colors of internal organs were evaluated. The Spleen, Testes, Pancreas, Lungs, Liver, 
Brain, Heart, Stomach, Intestine, Bone, Ovaries, and Kidney tissues were excised from all 
rats to visually detect gross lesions, and weighed to determine relative organs’ weights 
and preserved in 10% neutral formalin for histopathological assessment. The tissues were 
embedded in paraffin, and then sectioned, stained with haematoxylin and eosin and were 
examined microscopically. 
Statistical analysis 
 Values were represented as mean ± SEM. Data were analysed using one-way 
analysis of variance (ANOVA) and group means were compared using the Tukey-Kramer 
Multiple Comparisms Test using GraphPad Instat-V3 software. P values < 0.05 were 
considered significant( (trial drug 1 table  4-13) 
RESULTS AND DISCUSSION 
 The acute toxicity study of the Amukkara Kizhangu Chooranam indicated no 
changes in the behavior and in the sensory nervous system responses in the animals. Also 
no adverse gastrointestinal effects were observed in the mice used in the experiment. All 
the mice that received upto 2.0g/kg dose of the Amukkara Kizhangu Chooranam survived 
beyond the 24 hours of observation. Hence the dose was fixed as 100, 200 and 400mg/kg 
for further sub acute toxicity study. During the subacute toxicity tests, the results obtained 
on the average daily water, food intake and weekly weight gain are observed. The eating 
and drinking habit and behavior of all the animals used were normal in both vehicle-
treated and Amukkara Kizhangu Chooranam treated animals. The results obtained on the 
biochemical parameters of rats fed with Amukkara Kizhangu Chooranam for 28 days 
revealed that essential organs such as the liver, kidneys, spleen and testes were not 
adversely affected during the subacute administration. Acute and subacute oral 
administration of Amukkara Kizhangu Chooranam did not cause any significant changes 
in gross behavioural effects in rodents. 
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The feed conversion efficiency followed the same pattern, thus indicating a 
normal metabolism of the animals. Macroscopically, the liver, spleen, lungs, testis and the 
kidneys showed no discolouration and the textures were consistent when compared with 
the control group. Histopathological examination revealed that the spleens, livers, lungs, 
testes and the kidneys of rats administered with Amukkara Kizhangu Chooranam showed 
no differences relative to those of the control group at the two dose levels, though there 
was focal proximal tubular epithelial necrosis in the kidney at 400mg/kg.  
 These results indicate that Amukkara Kizhangu Chooranam at 400mg/kg body 
weight is not toxic to the liver, spleen and testes of rat but has a minor effect on the lungs 
and kidney. It is well established that changes in the lipid profile and total protein of 
serum could be indicative of perturbations in the liver or kidney following toxic injury. In 
conclusion, the present results show that Amukkara kizhangu Chooranam possesses very 
low toxicity as indicated in our rat model. No deaths or signs of toxicity were observed in 
the rats that received the Amukkara Kizhangu Chooranam up to an oral acute dose of 
2g/kg thus establishing its safety in use.  
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HISTO-PATHOLOGICAL SLIDES – TOXICITY STUDIES  
FOR TRIAL DRUG 1                                                                   
                       
                           Bone 400 mg                                                               Brain 400 mg 
                        
                                Heart  400mg                                                         Intestines400mg 
                     
                               Kidney 400mg                                                            Liver400mg 
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                           Lungs400mg                                                              Pancreas400mg 
 
                   
                             Spleen 400mg                                                            stomach400mg 
 
                     
                     Testis 400mg                                                               Ovaries 400mg 
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HYPOLIPIDEMIC ACTIVITY OF AMUKKARA KIZHANGU 
CHOORANAM(AKC)  IN CHOLESTEROL RICH DIET INDUCED 
HYPERLIPIDEMIC RATS 
AIM 
To evaluate the hypolipidemic  activity  of  Amukkara Kizhangu Chooranam   in  
cholesterol rich diet induced hyperlipidemic rats  
MATERIALS AND METHODS 
Chemicals: Cholesterol, Sodium cholate and coconut oil were all purchased from 
SD-fine chemicals, India, Lovastatin was procured form Ranbaxy labs. Ltd., Gurgaon, 
India. All other reagents used were of analytical grade. The various chemicals employed 
for different procedures were of analytical grade supplied by BDH Glaxo laboratories, 
E.Merck and Sigma Diagnostic (india) Pvt.Ltd. Commercially available BUF was 
purchased for the present work from a local shop. Standard Lovastatin at a dose of 10 mg 
kg-1 was prepared by suspending bulk in aqueous 0.5% Carboxy methylcellulose. 
Experimental animals - Adult albino rats 9-12 months old and weighing around 250g 
were selected (Approval number: XIII/ VELS/PCOL/36/2000/CPCSEA/ 
IAEC/08.08.2012) and and all the animals were fed with BUF for induction of lipid 
profile for one week. On eighth day the blood samples were collected and animals 
showing remarkable elevation of lipid parameter were divided into further five groups, 
six animals of each and those animals were treated with test drug AKC at the appropriate 
dose levels once daily in oral route with the help of oral gavage continuously. The total 
duration of treatment was 21days and the cholesterol rich diet along with normal pellet 
diet was given to the test animals to maintain the elevated biochemical profile during the 
drug treatment period. The grouping pattern was as follows. 
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Group 1: Normal 
Group 2: High cholesterol diet control 
Group 3: High cholesterol diet treated with AKC 100 mg kg-1 b.w., p.o. 
Group 4: High cholesterol diet treated with AKC 200 mg kg-1 b.w., p.o. 
Group 5: Standard Lovastatin 10 mg kg-1 body weight (b.wt.), orally (p.o.) 
Diet preparation- Normal rat feed supplied by Sai durga feeds, Bangalore was fed to 
normal control group in measured quantities and it was found that a rat consumed an 
average weight of 14g feed daily. The normal rat was powdered and mixed with fat so as 
to fix 21% fat in the diet for control, groups 2-5, and similar high fat diets mixed with 
AKC 100-200mg/kg. The mixture of feeds were wetted with a little water and made into 
balls and dried in an oven for feeding it daily. Water was supplied in bottles to each group 
so that controls and tests were paired fed. The body weight was measured at about every 
7 days interval.  
 After 21days of drug feeding the rats were sacrificed on overnight fasting. Their 
blood was collected in centrifuge tubes by punching the retro orbital vein and the serum 
was separated after an hour. It was used for the estimation of lipid parameters and enzyme 
activities. The liver was also collected and preserved in ice cold beakers for various 
estimations. Kits provided by sigma diagnostics Pvt. Ltd. Were used for lipid and enzyme 
estimations according to standard methods. Extractions of tissues were carried out for 
various estimations.  
Blood sample collection and analysis:  
 On the 8th and 28th day, blood was collected by retro-orbital puncture technique, 
under mild ether anesthesia after 8 h fasting and allowed to clot for 30 min at room 
temperature. Blood samples were centrifuged at 3000 rpm for 20 min. Serum was 
separated and stored at -20°C until biochemical estimations were carried out. Serum 
samples were analyzed spectrophotometrically for total serum cholesterol (TC), 
triglyceride (TG) and high density lipoprotein cholesterol (HDL-C) was estimated using 
diagnostic kits which were procured from Lab-Care Diagnostics Pvt. Ltd., Mumbai, India. 
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Very Low Density Lipoprotein (VLDL), High Density Lipoprotein ratio (HDL-C ratio), 
Atherogenic Index (AI) and low density lipoprotein cholesterol (LDL-C) were calculated. 
Extraction for cholesterol– Acute weighed (0.5g) tissue was ground with 4g of 
anhydrous sodium sulphate using mortor and pestle. An extract using chloroform 
methanol mixture (1:1) was made 1:5 volumes and diluted to 20ml and centrifuged. 2ml 
of this supernatant was evaporated and redissolved in 1ml acetic acid 0.05ml of this 
extract was used for the estimation of total cholesterol. Serum VLDL+LDL cholesterol 
was determined by substracting HDL cholesterol from total cholesterol. 
Extraction for AST and ALP – Accurately weighed 0.5g tissue was ground in a mortor 
with pestle under cold conditions. 2ml of phosphate buffer (PH   7.4) was added and 
centrifuged in a refrigerated centrifuge at 2000g. The supernatant was for the assay of 
enzyme. Serum lipid parameters such as total cholesterol, HDL cholesterol and 
VLDL+LDL cholesterol and serum enzyme such as aspartate transaminase (AST) and 
alkaline phosphate (ALP) were estimated by standard methods. 
Statistical analysis: Experimental results were Mean±SEM (Standard Error of Mean) of 
6 animals. The results were statistically analyzed using one-way Analysis of Variance 
(ANOVA) followed by Tukey’s multiple tests to determine level of significance. Data 
were considered statistically significant only when value of p<0.05. 
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RESULTS AND DISCUSSION 
 From the acute toxicity study, it was confirmed that the Amukkara Kizhangu 
Chooranam is non toxic upto 2000mg/kg on oral administration in mice. Hence, the one 
tenth of this maximum  tolerable dose and its lower dose was considered for further 
pharmacological study.  After 21days of AKC treatment at the different dose levels of 
cholesterol rich diet induced hyperlipidemic rats showed significant increase in body 
weight after fourteen days (P<0.01) when compared to normal control. The result on the 
lipid profile was observed that the diets containing BUF increased very significantly the 
lipid profile i.e., total cholesterol. The administration of AKC at 100 and 200mg/kg dose 
levels along with high fat diets significantly ameliorated the deleterious effects of these 
animal fats and in addition the 200mg/kg dose significantly increased HDL cholesterol 
which has a protective action against CHD.  
 The total cholesterol in the AKC 100 and 200mg/kg treated group showed 
142.00±4.37 and 138.81±3.48mg/dl respectively, whereas the hyperlidemic control 
showed 179.46±5.13mg/dl. Similarly, the triglyceride level was 159.33±4.48 and 
147.10±3.52mg/dl and in control it was 285.17±4.10mg/dl. The LDL level was 
significantly reduced in AKC 100 and 200mg/kg treated animals towards 41.64±3.00 and 
70.15±3.64 from 87.34±4.15mg/dl. In this it was noticeable that the lower dose group 
showing overall maximum beneficial effect in animal models. The high dose group 
showing moderate activity and the exact reason is not clear. The VLDL was effectively 
reduced to normal range on AKC treatment compared to control the effect is statistically 
significant and comparable to that of standard drug treatment.  
 The artheogenic Index i.e the ratio of total cholesterol/HDL cholesterol in the fat 
fed groups increased as 4.65±0.22 but after AKC treatment it was significantly altered to 
3.11±0.04 and 3.48±0.04 respectively. The AI in standard drug Lovastatin treated animals 
it was 2.86±0.06which was almost equivalent to normal. It was noted that the damage is 
not completely prevented by any of the above doses of AKC but their use may lessen the 
atherogenic effects of the animal fats in diets. It appears the BUF is more harmful in their 
hyperlipidemic and related effects. Most of the altered parameters are ameliorated 
significantly and the lipid profile was better controlled that the enzyme levels on 
incorporation of any of the two doses in the high fat diets.  
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 The SGOT and SGPT levels were altered in drug AKC treated animals to 
159.87±5.75, 198.40±5.44 and 64.11±2.31, 101.02±2.64 from 234.48±5.50 and 
130.40±4.56 respectively. The total protein, Urea and Glucose levels were also altered 
towards normal on AKC treatment. In treated groups a significantly reduced level of 
HMG CoA reductase, the rate limiting enzyme in cholesterol synthesis may be 
responsible for the fall in cholesterol level. Modern lipid lowering agents i.e., statins 
(Atrovastatin, Simvastatin, Rosuvastatin etc.) are expensive. The most important adverse 
effects of statins are liver and muscle toxicity. Other risk factors are hepatic dysfunction, 
renal insufficiency, hypothyroidism, advanced age and serious infections. The liver, Heart 
and Kidney weight was signicantly increased in hyperlipidemic rats which was 
normalized in the AKC treated animals.   
The hyperlipidemic and particularly the hypercholesterolemic effects of the 
animal fats may be due to the higher percentage of saturated fatty acids. i.e. 54-68% in 
them. A richer content of cholesterol on BUF may account for a greater 
hypercholesterolemic effect. Hyperlipidemia is one of the major risk factor for 
cardiovascular disease like atherosclerosis. Atherosclerosis is a generalized and 
inflammatory vascular disease frequently associated with renal disease and dysfunction. 
Diverse renal vascular diseases, including atherosclerotic renal vascular disease, account 
for more than one third of all cases of end stage renal disease. An enhancement in the 
activities may be due to various reasons. viz;  as a result of stimulation of different 
metabolic pathways leading to the synthesis of cholesterol from dietary fats and also from 
the interconversion of aminoacids and breakdown of phospholipids and related 
compounds under a stress of high fat diets.  
 All these results emphasise the need for incorporation of the AKC in our daily diet 
as a measure to protect our body from atherosclerosis and related diseases. Abundant 
evidence supports the link between hyperlipidemia and atherosclerosis. Clinical trials 
showed that lowering lipids reduces the morbidity and mortality associated with 
cardiovascular complications. It is well known that HDL-Cholesterol levels have a 
protective role in Coronary artery disease. Similarly increased level of serum LDL-
cholesterol results in increased risk for the development of atherosclerosis.  
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The increased level of HDL- cholesterol and decreased cholesterol level along 
with its LDL fraction which is evident from the results could be due to an increased 
cholesterol excretion and decreased cholesterol absorption through gastro intestinal tract. 
Thus the decreasing cholesterol levels in the body under the influence of AKC could have 
enhanced the enzymatic by a positive feedback mechanism. The rats fed with high 
cholesterol diet exhibited significant increase in TC, LDL-C and VLDL and significant 
decrease in HDL-C, HDL-C ratio as compared to the normal animals.  
CONCLUSION 
 From the toxicity study, it was established that the Amukkara Kizhangu 
Chooranam is non toxic upto 2000mg/kg. The test drug Amukkara Kizhangu Chooranam  
for  21 days treatment significantly lowered the total cholesterol, triglycerides and other 
biochemical parameters elevated on cholesterol rich diet.  Histopathological reports 
substantiate the beneficial effect of test drug on the reduction in the fat deposition in the 
liver. Based on the above results, it can be concluded that the Amukkara Kizhangu 
Chooranam is an effective drug in the treatment of hyperlipidemia at the dose level of 
100mg/kg. The overall beneficial effect of Amukkara Kizhangu Chooranam was 
observed in low dose treatment only in animal models.  
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HISTO-PATHOLOGICAL SLIDES –  PHARMACOLOGICAL  STUDIES  
FOR TRIAL DRUG 1                                                       
                                
      Normal control                                                                 Hyperlipidemic control –cells   
                                                                                                     with fat Deposition.                                              
                                 
     AKC 100mg/kg moderate                                            AKC 200 mg/kg-intact cells with  
        accumution  of fats                                                        normal Cellular architecture. 
                                            
                                                           Lovastatin treated 
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HYPERLIPIDEMIA12 
 Hyperlipidemia is a heterogeneous group of disorders characterized by an excess 
of lipids in the bloodstream. These lipids include cholesterol, cholesterol esters, 
phospholipids, and triglycerides 
SYNONYMS 
 Hypercholesterolemia 
 Hypertriglyceridemia 
 Hyperlipoproteinemia 
 Dyslipidemia 
 High serum cholesterol 
EPIDEMIOLOGY: 
 The World Health Organization (WHO) reports that high cholesterol contributes 
to 56% of cases of Coronary Heart Disease worldwide and causes more than 4 million 
deaths each year. 
AGE 
 Total and LDL-C rise about 20% in men aged 20 to 50 years 
 Total and LDL-C rise steadily about 30% in women aged 20 to 60 years 
 Younger women have lower levels than men 
 Homozygous familial hypercholesterolemia manifests itself from birth 
GENDER 
 Incidence is higher among men than women. 
SOCIOECONOMIC STATUS 
 Awareness of dietary factors that affect plasma lipid levels increases with higher 
educational levels 
 Low-cost food items are often higher in saturated fats and lower in nutritional 
value 
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ETIOLOGY: 
Common causes 
 Familial combined hypercholesterolemia is the most common primary lipid 
disorder, characterized by moderate elevation of plasma triglycerides and 
cholesterol and reduced plasma HDL-C 
   Familial Hypertriglyceridemia 
Dietary causes include: 
 Fat intake per total calories greater than 40% 
 Saturated fat intake per total calories greater than 10% 
 Cholesterol intake greater than 300 mg per day 
 Habitual excessive alcohol use 
Lifestyle contributing factors include: 
 Habitual excessive alcohol use 
 Obesity 
 Lack of exercise 
Drugs associated with Hyperlipidemia include: 
 Anabolic steroids 
 Retinoids 
 Birth control pills and estrogens 
 Corticosteroids 
 Thiazide diuretics 
 Protease inhibitors 
 Beta-blockers 
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SYMPTOMS:   
Usually asymptomatic 
Primary type I: 
 Type I Hyperlipidemia is quite uncommon according to Harrison's Principles of 
Internal Medicine. It is also called familial Hyperchylomicronemia and Buerger-Gruetz 
syndrome. This disorder causes high chylomicrons, the proteins that carry fat from the 
intestine to the liver. It can cause abdominal pain, pancreatitis, fat deposits in the skin and 
eyes and a large liver and spleen. Treatment involves eating a healthy diet. 
Primary type II: 
 Type II Hyperlipidemia is divided into type IIa and type IIb. Type IIa is also 
known as familial hypercholesterolemia and type IIb is also known as familial combined 
Hyperlipidemia. Type lIa results in high LDL, or "bad" cholesterol, levels. Type IIa also 
raises levels of LDL, as well as a similar lipoprotein, VLDL, which results in elevated fat 
levels in the blood. These conditions cause fat deposits under the skin and around the 
eyes, and are treated medically and with dietary control. 
 Primary type III: 
 Type III Hyperlipidemia is an uncommon disorder also known as familial 
Dysbetalipoproteinemia, remnant removal disease or broad-beta disease. It results in high 
levels of LDL and carries a very significant risk of heart disease. It is treated with 
medicine and diet. 
Primary type IV: 
 Type IV is also known as familial Hyperlipidemia. Cholesterol levels tend to be 
normal and fat is elevated in the blood as VLDL levels are elevated. It is also treated with 
medicines and proper diet. 
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Primary type V: 
 Type V is another rare type that is characterized by elevated chylomicrons and 
VLDL. It is also known as endogenous Hypertriglyceridemia. 
Accquired: 
 According to "Greenspan's Basic & Clinical Endocrinology" by Dr. David 
Gardner, acquired Hyperlipidemia is high fat and cholesterol in the blood due to other 
conditions or medications. Diabetes, low thyroid hormone levels, kidney disease and 
some other metabolic disorders cause Hyperlipidemia. Some drugs can also cause 
Hyperlipidemia, including alcohol, diuretics, estrogens and beta blockers. 
 Complications:  
Arteriosclerotic heart disease: 
 A serious complication associated with hyperlipidemia is a condition called 
arteriosclerotic heart disease, coronary heart disease or hardening of the arteries. Plaque 
formation narrows the arteries and prevents blood and oxygen from reaching the heart. As 
the disease progresses the blood vessels may become so constricted that blood and 
oxygen are unable to reach the heart, resulting in breathing problems, chest pain or heart 
attack. 
Heart attack: 
 People who have Hyperlipidemia are at risk for an early heart attack .A heart 
attack can occur when blood clots prevent blood flow through the coronary arteries to the 
heart. When the heart does not receive an adequate amount of blood and oxygen, the heart 
muscle may become damaged or die.  Hyperlipidemia may experience a heart attack 
when cholesterol plaques accumulate in the coronary arteries and block blood and oxygen 
from reaching the heart. 
Stroke: 
 A stroke can occur when reduced blood flow to the brain deprives the brain tissue 
of oxygen and nutrients. When the brain does not receive blood and oxygen for several 
minutes, the brain cells begin to die. Hyperlipidemia may experience a stroke when fatty 
plaques loosen from their constricted coronary arteries, lodge in the brain and block blood 
flow to that part of the body. 
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CLINICAL STUDY 
Clinical trial on Amukkara Kizhangu Chooranam in the management of 
Athimetham(Hyperlipidemia) for Hypolipidemic activity  got approved by institutional  
ethical committee, NIS on 24/12/2011. Approval no is NIS/IEC/2011/3/13b-24/12/2011. 
 Based on the protocol approved by IEC,NIS the study was conducted on 
Athimetham (Hyperlipidemia) patients.The study was conducted in National Institute of 
Siddha , Ayothidass  Pandithar Hospital, Chennai -47. 
Study type  :          pilot study 
Sample size :  20 patients 
SUBJECT SELECTION 
Patients reporting at OPD of Ayothidoss Pandithar hospital with inclusion criteria 
were subjected to screening test & documented using screening proforma. 
 INCLUSION CRITERIA: 
 Age  :  20-60 years. 
 Sex  :  male and female 
 Weight :  male above 50 kg 
     Female above 45 kg. 
 Increased levels of any one of the following: 
 Serum total cholesterol (220-400mgs/dl) 
 Serum triglycerides.(170-350mgs/dl) 
 Low density lipo protein.(150-300mgs/dl) 
 Very low density lipo protein.(50-100mgs/dl) 
 Family  history of hyperlipidemia. 
            Patient  who was already diagnosed as hyperlipidemia. 
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Patients   who are  willing to provide blood for investigations before and after 
treatment. 
 Patients   who are  willing to attend OPD once in 7 days. 
EXCLUSION CRITERIA: 
 Chronic renal failure  
 Alcoholism 
 Liver disorder 
 Pregnancy and lactation 
 Drugs 
 Any other serious illness 
WITHDRAWL CRITERIA: 
 development of any adverse reaction 
 occurrence of any other serious illness 
 Non-co-operation of the patient 
 
Trial drug        :    Ammukara  Kizhangu  Chooranam 
          
Dose              :     2g twice daily. 
 
Vehicle           :  honey 
 
Duration         :  30 days. 
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Conduct of the study: 
Athimetham patients who  satisfied the inclusion and exclusion criteria were 
admitted to the clinical trial. Patients informed consent was obtained. Routine  
haematological,urine  investigations along with lipid profile  were assessed before and 
after  treatment. Trial drug  was issued to them once in 7 days .Each  time they were 
assessed clinically .Haematological investigations were taken before and after treatment. . 
Patients was informed to report about adverse effects if any. 
Among 20 patients 45%  patients were male 55%were female (trial drug 1 table 
20 ,trial drug 1 chart 1) 
Among 20 patients 40% patients were in the age group of  30-45 years. (trial drug 
1 table 20, bar diagram 8 ) 
Among 20 patients 60 %patients were in the age group of  45-60 years. (trial drug 
1 table 20) 
Among 20 patients, 16 patients showed increase in serum total Cholesterol ,11 
patients showed increase in LDL, 10 patients sowed increase in VLDL and 18 patients 
showed increase in TGL. 
After the treatment with Amukkara Kizhangu Chooranam for 30 days, among 20 
patients 80% showed decrease in serum total cholesterol, 70% showed decrease in TGL, 
45% showed decrease inLDL,40%showed decrease in VLDL. No adverse effects found 
during the conduct of  study . (trial drug  table  21) 
Amukkara  Kizhangu Chooranam   reduced serum total Cholesterol ,TGL ,LDL 
and VLDL and it is  statistically significant. 
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DISCUSSION 
The principle aim of this study was to assess the pre-clinical safety and efficacy 
and to evaluate the therapeutic efficacy of the drug Amukkara Kizhangu Chooranam in 
the management of Athimetham (Hyperlipidemia). 
The literary evidence from the text  Gunapadam mooligai vaguppu  and modern 
science reviews strongly supports the Hypolipidemic  activity of the drug.  
Biochemical analysis: 
The biochemical analysis of the drug reveals the presence of alkaloids ,iron, 
glycosides. 
Toxicological studies: 
   In acute toxicity study  the  results indicate that no deaths or signs of toxicity 
were observed in the rats that received  Amukkara Kizhangu Chooranam up to an oral 
acute dose of 2g/kg thus establishing its safety in use.  
 During the sub acute toxicity studies  Amukkara Kizhangu Chooranam at 
400mg/kg body weight is not toxic to the liver, spleen and testes of rat but has a minor 
effect on the lungs and kidney.  
Pharmacological studies: 
The test drug Amukkara Kizhangu Chooranam  for  21 days treatment 
significantly lowered the total cholesterol, triglycerides and other biochemical parameters 
elevated on cholesterol rich diet.  Amukkara Kizhangu Chooranam is an effective drug in 
the treatment of hyperlipidemia at the dose level of 100mg/kg. 
In treated groups a significantly reduced level of HMG CoA reductase the rate 
limiting enzyme in cholesterol synthesis may be responsible for the fall in cholesterol 
level. 
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Clinical observation: 
  In case of  clinical trial , the treatment with Amukkara Kizhangu Chooranam for 
30 days,80% showed decrease in serum total cholesterol , 70% showed decrease in 
TGL,45% showed decrease in LDL,40% showed decrease in VLDL. 
The drug has significantly reduced the serum cholesterol and triglyceride level.  
So  the drug  may contribute to prevent the risk of cardiac disease.  
Bio-statistics: 
Statistically, the paired ‘t’ test shows statistical significance for the drug 
Amukkara Kizhangu Chooranam in the management of Athimetham. 
‘p’ value for S.T.cholesterol is 0.001 .TGL is 0.002  (TRIAL DRUG 1 table 22). 
Previous  studies : 
Previous studies showed that the herb possess immuno modulator , haemopoetic 
,anti tumor ,anti depressant activity .30 
Another study proved that flavanoids of withania somnifera WSREt and WSLEt 
showed hypoglycemic and  hypolipedemic activities in alloxan induced diabetic rats. 4  
Siddha  Aspect: 
«ÓìÌÃ¡ì¸¢Æí¸¢ý  
Í¨Å   : ¨¸ôÒ  
Å£Ã¢Âõ  : ¦ÅôÀõ 
À¢Ã¢×   : ¸¡÷ôÒ. 
¸¡÷ôÒ Í¨Å ¯¼ü À¨º¨ÂÔõ , ¦¸¡Øô¨ÀÔõ,Å ü ø ¸Àò É¡ø ¯ñ¼¡Ìõ 
Ð÷ ¨ÃÔõ ÅÃðÎõ .13,14 
 
Athimetham is one of the kabam related disorder .Since  Amukkara  Kizhangu  
Chooranam  has  kaarppu suvai  it  equalizes  the increased  kabam humour  it and will 
reduce the lipids as mentioned in siddha text. 13, 14 
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The present study is unlike from  previous studies on the subject of  suvai basis  , 
inducing hyperlipidemia ,dosage form, vehicle and includes clinical trial. 
Further the precise mechanism and the active constituents of Amukkara Kizhangu 
Chooranam which is responsible for its Hypolipidemic activity and related 
pharmacological responses are still to be determined and further chronic toxicological 
studies are also to be established. 
Abundant evidence supports the link between Hyperlipidemia and atherosclerosis. 
Increased level of serum LDL-cholesterol and TGL  results in increased risk for 
the development of atherosclerosis. As per the above studies   Amukkara Kizhangu 
Chooranam may prevent the mortality and morbidity due  to atherosclerosis in case of 
cardio vascular diseases  and stroke. 
So Amukkara  Kizhangu  Chooranam  will be a  better choice of drug in the 
management of  Athimetham(Hyperlipidemia). 
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SUMMARY 
 
 The literary evidence strongly supports the  hypolipidemic  activity of  Amukkara 
Kizhangu  Chooranam. 
 The drug   Amukkara Kizhangu  chooranam  has been  selected for this study to 
evaluate its hypolipidemic  activity in the management  of 
Athimetham(Hyperlipidemia). 
 Biochemical analysis of the  drug  Amukkara Kizhangu Chooranam  reveals the 
presence of iron,glycosides, alkaloids & Amino acids. 
 In acute toxicity study  all the mice that received upto 2.0g/kg dose of the 
Amukkara Kizhangu Chooranam survived beyond the 24 hours of observation. No 
deaths or signs of toxicity were observed in the rats that received the Amukkara 
kizhangu Chooranam up to an oral acute dose of 2g/kg thus establishing its safety 
in use.  
 During the sub acute toxicity studies  Amukkara kizhangu Chooranam at 
400mg/kg body weight is not toxic to the liver, spleen and testes of rat but has a 
minor effect on the lungs and kidney.   The present results show that Amukkara 
kizhangu Chooranam possesses very low toxicity as indicated in our rat model. 
 The test drug Amukkara Kizhangu Chooranam treatment significantly lowered the 
total cholesterol, triglycerides and other biochemical parameters elevated on 
cholesterol rich diet 
 A number of 20 patients were included in clinical trial  satisfying the inclusion 
criteria . 
The drug Amukkara Kizhangu Chooranam was given to the patients once in 7 
days for 30 days. 
 Among 20 patients 80% showed decrease in serum total cholesterol, 70% showed 
decrease in TGL, 45% showed decrease inLDL, 40% showed decrease in VLDL 
after the treatment with Amukkara Kizhangu Chooranam for 30 days. 
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 No adverse effect was developed during the treatment period. 
 Statistical analysis- paired ‘t’ test,  showed  “P” value for  Serum  total 
Cholesterol is 0.001 ,LDL is 0.14 ,VLDL is 0.037 and TGL IS 0.002. So the drug 
Amukkara Kizhangu Chooranam  considered to be statistically significant in the 
management of Athimetham . 
 The drug  Amukkara Kizhangu Chooranam  ensures 
 No significant  toxicity 
 Hypolipidemic  Activity. 
 No side effects 
 No undoing effects 
 Encouraging clinical results. 
 From the clinical  studies and statistical analysis it is proved that the drug 
Amukkara Kizhangu Chooranam  is statistically significant for  hypolipidemic  
activity in the 
management of  Athimetham (Hyperlipidemia) in prospective days. 
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CONCLUSION 
 The literature and research journal review of the plant supports  that it has 
Hypolipidemic activity. 
 The safety studies (acute toxicity and repeated oral toxicity) studies conducted 
revealed that the trial drug Amukkara Kizhangu Chooranam  is safe. Hence it can 
be reasonably assumed that the drug is safe for human use. 
 The pharmacological study conducted in animal model showed significant 
Hypolipidemic activity. 
 Clinical study revealed the therapeutic efficacy of the trial drug by showing, 
reduction in serum total cholesterol ,TGL significantly. There were no adverse 
reactions reported  during the clinical trial. 
 Hence, the drug Amukkara Kizhangu Chooranam  can be used in the 
management of Athimetham (Hyperlipidemia) 
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INTRODUCTION 
Siddha System is one of the traditional and pioneer systems of medicine. Siddha 
medicines are broadly classified in to internal medicines and external  medicines each of 
32 types. They are prepared from herbs, metals, minerals and biological resources. A total 
number of   4,448 diseases is mentioned in Siddha text as well as with  line of treatment. 
Kalladaippu is one of the diseases mentioned in siddha text. Kalladaippu can be 
correlated with renal calculus which is the presence of stones in the kidneys, ureters  and 
bladder. Mankind has been affected by the urinary stones since centuries. Renal calculus 
is one of the most common urological disorder. 
Archeological findings give profound evidence that humans have been suffered 
from kidney and bladder stones for centuries. Bladder stones were more prevalent during 
older ages, but kidney stones became more prevalent during the past 100 years15 The first 
evidence of urinary stone  was found in Egyptian mummy E1amrah eygpt at 4800B.C.16. 
The high incidence and recurrence rate contribute to making the urolithiasis a 
serious social problem. Nowadays, urolithiasis must be considered a 'disease in evolution' 
for several reasons, such as epidemiological changes, evolution of the methods used for 
diagnosis, and the treatment and prophylaxis of the population considered 'at risk' of stone 
disease.17 
The overall probability that an individual will form stones varies in different parts 
of the world. The risk of developing urolithiasis in adults appears to be higher in the 
western hemisphere (5–9%) in Europe, 12% in Canada, (13–15%) in USA than in the 
eastern hemisphere (1–5%), although the highest risks have been reported in some Asian 
countries such as Saudi Arabia (20.1%).18 
It is estimated that at least 10% of the population in the industrialized part of the 
world is afflicted by urinary tract stone disease. Kidney stones are common in 
industrialized nations with an annual incidence of 0.5% to 1.9%.  
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Urinary stone constitute one of the commonest diseases in our country and pain 
due to kidney stones is known as worse than that of labour pain. In India, approximately  
5 -7 million patients suffer from stone disease and at least 1/1000 of Indian population 
needs hospitalization due to kidney stone disease.16   
 In India upper and lower urinary tract stones occur frequently but the incidence 
shows wide regional variation. The incidence of renal calculi is comparatively low in the 
southern part of country compared to other parts. 19    
It has been well documented that the incidence of urinary stones is higher in 
countries with warm or hot climates, probably due to low urinary output and scant fluid 
intake.20 12% of people have stone in their life time. Highest incidence of urinary stone in 
the age group of 30-45 years and declines  after  the age of 50. 12%  of men and 5 % of 
women suffer from urinary stone by the age of 70. 50% have their recurrence in 5-10 
years. 7-10 of every1000 hospital admission is a renal stone .16  
First-degree relatives of stone-formers have a 2-16 times higher risk of developing 
renal stones when compared with the general population.  In a stone-former, the 
probability of having a relative with stones may be as high as 35-65% as compared with 
5-20% probability in a non-stone-former.18 
Treatment options and conservative measures, as well as ‘surgical’ interventions 
have also been known for a long time. In the recent few days new modern techniques are 
available to treat renal calculi which are not cost effective to low and middle socio-
economic group. Even though our current preventive measures are definitively good the 
incidence and recurrence has not yet reduced markedly.  
Several  Siddha medicines evidenced lithontriptic activity in the management of 
renal calculi. Sarva Noi Linga Chenduram is one of the herbo-mineral formulation which 
is  mentioned in siddha text  for Kalladaippu32.  
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The ingredients of   Sarva Noi Linga Chenduram   are Lingam and Venkaram. In 
siddha text  it is mentioned that  “«ôÒ â¾ ¯ÚôÒ¸ ¢ø ¯ñ¼¡Ìõ §¿¡ö¸¨  
¿£ìÌõ” for Lingam and also Venkaram possess lithontriptic,diuretic activity. The 
efficacy of this drug for Kalladaippu  has not been evaluated so far. 
 Hence the researcher has selected Sarva Noi Linga Chenduram to evaluate its 
lithontriptic activity and therapeutic effect in the management of  Kalladaippu. 
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Aim: 
    To evaluate the safety and efficacy of “Sarva Noi Linga Chenduram”  for   
Lithontriptic  activity  in the management of  Kalladaippu [Renal calculi ] 
OBJECTIVE: 
Primary objective: 
 To evaluate the lithontriptic activity of “Sarva Noi Linga Chenduram” for 
Lithontriptic  activity in preclinical studies. 
Secondary objective: 
Bio –chemical analysis. 
Atomic Absorption  spectrometer  Study. 
To evaluate the therapeutic efficacy  of  “Sarva Noi Linga Chenduram”  in clinical 
trial for Lithontriptic activity   in the management of  Kalladaippu[Renal Calculi]. 
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MATERIALS AND METHODS 
STANDARD OPERATIVE PROCEDURE: 
COLLECTION AND AUTHENTICATION OF RAW DRUG: 
The raw drugs  were procured from raw drug store in  Chennai and authenticated 
by competent authority of Department of Gunapadam ,National Institute of Siddha, 
Chennai. 
PREPARATION OF THE MEDICINE: 
INGREDIENTS: 
Purified Lingam (Cinnabar) - 35g 
Purified Venkaram (Borax) - 140g 
PURIFICATION METHODS: 
Purification of Lingam: 21 
  It was kept on a mud vessel and heated in low fire. The juices of citrus lemon, 
Acalypa indica, cow’s milk are mixed  in equal proportions. The mixed liquid was poured 
drop by drop on lingam while heating.    
Purification of Venkaram: 22 
 Venkaram ground  by the citrus lemon juice and then dried it  
METHOD OF MEDICINE PREPARATION: 
 Lingam was grinded into tiny particles. Venkaram was  placed in a mud vessel 
and heated in a low fire. When venkaram started melting purified lingam was sprinkled 
little by  little. It had to be mixed well. Before melting of venkaram all quantity of lingam 
was sprinkled. After that the medicine was taken away from the heat. By the time, it got  
completely condensed. Then it was well ground in the kalvam and stored in an air tight 
container.  
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LABELLING: 
Name of the preparation :  Sarva Noi Linga Chenduram. 
  Quantity of the drugs  :  Lingam 35g, Venkaram140g. 
 Dose    : 130 mg, twice a day. 
 Adjuvant or Vehicle  :  Mullangi (Raphanus sativus) juice. 
 Indication   : Kalladaippu [Renal calculi] 
 Date of manufacturing : 17/3/12 
 Date of expiry   : 75 years from the date of manufacturing 
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LINGAM BEFORE PURIFICATION               LINGAM AFTER PURIFICATION 
 
 
                        
                                               
                                                      VENKARAM 
BEFORE PURIFICATION                                           AFTER PURIFICATION 
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                                          SARVA NOI LINGA CHENDURAM  
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SIDDHA ASPECT 
 
                                                  Ä¢í¸õ25  
§ÅÚ ¦ÀÂ÷¸û: 
     ¬ñÌÈ¢ 
     íÌÄ¢¸õ 
     Ã¡ºõ 
     ¸¨¼ÅýÉ¢ 
     ¸÷ôÀõ 
     ¸Ä¢ì¸õ 
     ¸¡ïºÉõ 
     ¸¡Ã½õ 
     ºñ¼¸õ 
     ºÁÃºõ 
     º¡É¢Âõ 
     ¦ºóàÃõ 
     Á½¢Ã¡¸õ 
     Á¢§Äîºõ 
     ÅÉ¢ 
     ÅýÉ¢ 
      
Ì½õ: 
    ¾üÌ ¸Éò ¾ý¨ÁÔõ, ¦¿ÕôÀ¢Ä¢¼ô Ò¨¸Ôó ¾ý¨ÁÔõ ¿£Ã¢ø 
¸¨ÃÂ¡ò¾ý¨ÁÔõ ¯ñÎ, Å¡º¨ÉÔõ ¯Õº¢Ôõ ¸¢¨¼Â¡. 
 
¦À¡Ð Ì½õ: 
   "  §À¾¢ÍÃï ºó¾¢ ¦ÀÕÅ¢Ã½ ¿£¦Ã¡Î¾ 
      ¸¡¾¸Ê ¸¡ºí ¸ÃôÀ¡ýÒñ-§½¡¾ 
      ×Õ×Ä¢í¸ ºí¸¾Á¡ äÚ¸ðÊ Ôõ§À¡í 
      ÌÕÅ¢Ä¢í¸ ºí¸Áò¨¾ì ¦¸¡û.  " 
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   "  ¬¾¢ Â¢Ã¾×Õì ¸¡¾Ä¡ü º¡¾¢Ä¢í¸ 
     §Á¡¾¢ Ä¢Ã¾Ì½ ÓüÚ¼Ä¢ü-È£ÐÒÃ¢ 
     Ìð¼í ¸¢Ãó¾¢ ¦¸¡ÎïÝ¨Ä Å¡¾Ó¾ 
     Öð¼íÌ  §¿¡ö¸¨ §Â¡ð Îõ." 
 
§¾¡üÈò¾¢ø À¡¾Ãº ¯Õì¸¡¸¢Â º¢Åó¾ ¿¢Èò¨¾ ¯¨¼Â 
º¡¾¢Ä¢í¸Óõ,«Ð §º÷ó¾ ÁüÈ ÁÕóÐ¸Ùõ, «ó¾ Ãº Ì½ò¨¾ì ¦¸¡ñÎ 
ÐýÀò¨¾ ¯ñÎÀñÏ¸¢ýÈ§À¾¢, ÍÃõ, ºó¿¢À¡¾õ, ¾£Ã¡ôÒñ¸û, 
«¾¢ãò¾¢Ãõ,¸¡½¡ì¸Ê, Å¢¼õ, ¸¡ºõ, ¸ÃôÀ¡ý, º¢ÃíÌ, ¦º¡øÅ¾üÌõ 
À¡÷ôÀ¾üÌõ, ¦ÅÚôÒò §¾¡ýÚõ ÀÃ× Ñ½¡ì¸¡öì ¸¢Ãó¾¢ ,Ìð¼õ,¦¸¡Î¨Á 
¦ºö¸¢ýÈ Ý¨Ä Å¡¾ §¿¡ö Ó¾Ä¢Â¨Å¸¨ Ôõ, ÁüÚõ ¯¼Ä¢ø Á¨ÈóÐ 
ÕìÌõ À¢½¢¸¨ Ôõ ¿£ìÌõ.  
 
    " ¿¢Äò¾¢ ¦ÄØó¾ À¢½¢¿£í¸¡ì ¸¢Ãó¾¢ 
ºÄòÐ¼§É Ý¨Ä¦ÅÊ¾¡É¸üÚõ-ÀÄò¾¾¡õ 
º¡¾¢Ä¢í¸ò ¾¢ýÌ½ò¨¾î º¡üÈ¢§Éý ºýÉ¢Ó¾ø 
µÐÍÃõ §À¡§Á ´ ¢óÐ." 
 
¿¢Äò¦¾Øó¾ À¢½¢-À¢Õ¾¢Å¢ â¾ ¯ÚôÒ¸ ¢ø ¯ñ¼¡õ §¿¡ö¸û;ºÄôÀ¢½¢-
«ôÒ â¾ ¯ÚôÒ¸ ¢ø ¯ñ¼¡Ìõ §¿¡ö¸û. 
 
Íò¾¢ Ó¨È¸û: 
 ÀÆîº¡Ú,ÀÍõÀ¡ø,§ÁÉ¢îº¡Ú õãý¨ÈÔõ ºÁ¦Å¨¼ÜðÊ, 
Ä¢í¸ò¾¢üÌî ÍÕì¸¢ð¦¼Îì¸, Ð Íò¾¢Â¡õ.  
 Ó¨ÄôÀ¡Ä¢Öõ , ±ÖÁ¢îºí¸É¢ Ãºò¾¢Öõ Ó¨È§Â ´ù¦Å¡Õ 
¿¡û  °È ¨Åì¸ §ÅñÎõ. 
« ×: 
         ¯û ÁÕóÐ : 10 ¯Ùó¦¾¨¼ (650 Á¢ ¸¢ ) Å¨Ã ¯ûÙìÌ 
¦¸¡Îì¸×õ 
             Ò¨¸   : 1/2 ÅÃ¡¸ý. 
        (¨À ƒ ¸øÀõ). 
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¦Åí¸¡Ãõ 25(a) 
 
§ÅÚ ¦ÀÂ÷¸û : 
 
   ¦À¡Ã¢¸¡Ãõ  
   ¸¡Ãõ 
   ¯Õì¸¢Éõ 
   ¯ÕìÌ Á¢ò¾¢Ãý  
   ¼í¸½õ 
   àÁò¨¾Â¼ì¸¢  
 
Í¨Å: 
  É¢ôÒ¼ý ÜÊÂ ÐÅ÷ôÒî Í¨Å¨Â ¯¨¼ÂÐ  
 
Å£Ã¢Âõ :  ¦ÅôÀõ 
 
    “¦Åí¸¡Ãõ ¦Åö¦¾É¢Öõ §¿¡ö ¾£÷ìÌõ” ±ýÈ «ÊÂ¡ø ¯ÉÃÄ¡õ. . 
 
¦ºö¨¸ : 
 
 Ì ¢÷îº¢ ¯ñ¼¡ì¸¢. 
 º¢Ú¿£÷¦ÀÕì¸¢ 
 ÕÐ¯ñ¼¡ì¸¢ 
 À¢ÃºÅ¸¡Ã¢ 
 ¸ü¸¨Ãîº¢   
 
¦Å ¢Â¡ðº¢: 
 
 ºÁÉ¸¡Ã¢ 
 ¯¼ø §¾üÈ¢ 
 «Ø¸Ä¸üÈ¢ 
 ÐÅ÷ôÀ¢ 
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¦À¡Ð Ì½õ : 
 
"¦º¡È¢Ò¨¼¦Âñ ÌýÁ¿¨Á §º¡Ã¢ Â¡ºõ 
  ÀÈ¢¸¢Ã¸½¢ ¸øæÉõ Àý§É¡ö-¦ÉÈ¢¨Âò 
¾¼í¸½í¸ Àí¸¢ÕÁ¢ º÷ôÀÅ¢¼ï ºó¿¢ 
Â¢¼í¸½í¸ Äì¸ü§À¡ ¦Áñ." 
¦Åí¸¡Ãò¾¢É¡ø, ¾Å¨ î ¦º¡È¢, Ò¨¼, ±ñÅ¨¸ì ÌýÁõ, ¾¢É×, 
Ãò¾ãÄõ, ´ØìÌì ¸¢Ã¸½¢, «ŠÁÃ¢, ÀíÌÅ¡¾õ, Àø §¿¡ö, ¿¡ ÅÆ¢¨Â 
¾Îì¸¢ýÈ ãò¾¢Ã¸¢Ã¢îºÃí¸û ,¸À¡¾¢ì¸õ, ÒØ ,À¡õÒ Ó¾Ä¢Â¨Å¸ ¡ø 
¯ñ¼¡Ìõ ¿ïÍ,ºó¿¢À¡¾õ Ó¾Ä¢Â §¿¡ö¸û ¿£íÌõ. 
Íò¾¢ Ó¨È¸û: 
o ÀÍÅ¢ý º¡½ôÀ¡Ä¢ø ¾¨Éì ¸ØÅ¢ ¯Ä÷ò¾  §ÅñÎõ. 
o ¾¨É ¿£÷ÅüÚõÀÊ ¦À¡Ã¢òÐì ¦¸¡û  §ÅñÎõ. 
o ¾¨Éî ºðÊÂ¢ø ðÎô ¦À¡Ã¢òÐì ¸¡ÊÂ¢Ä¡ÅÐ 
ÀÆîº¡üÈ¢Ä¡ÅÐ «¨ÃòÐ ¯Ä÷ò¾¢ ±Îì¸ §ÅñÎõ 
o ÀÆîº¡üÈ¢Ä¡ÅÐ «Ã¢º¢ì ¸Ø¿£Ã¢Ä¡ÅÐ «¨ÃòÐ ¯Ä÷ò¾¢ì 
¦¸¡û  §ÅñÎõ 
¯À§Â¡¸í¸û: 
¦À¡Ã¢ò¾ ¦Åí¸¡Ãò¨¾ 5 (650 Á¢ ¸¢Ã¡õ) Ó¾ø 10 ÌýÈ¢¦Â¨¼ (1.3 
¸¢Ã¡õ) Å¨Ã ¿£Ã¢ø §À¡ðÎì ¦¸¡Îì¸ ¿£÷ì¸ðÎ Ì½Á¡Ìõ. 
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MINEROLOGICAL ASPECT 
LINGAM- CINNABAR 23, 24 
Cinnabar: 
Cinnabar is a  primary ore of mercury, a pigment and as a minerals specimen  
which was mined by the Roman Empire for its mercury content and it has been the main 
ore of mercury throughout the centuries. 
Chemical formula :   HgS, Mercury Sulfide. 
Class   :  Sulfides and Sulfosalts  
Occurrence 
 Generally cinnabar occurs as a vein-filling mineral associated with recent volcanic 
activity and alkaline hot springs. Cinnabar is deposited by epithermal ascending aqueous 
solutions (those near surface and not too hot) far removed from their igneous source. 
PHYSICAL CHARACTERISTICS: 
 Color is a bright scarlet or cinnamon red to a brick red.  
 Luster is adamantine to submetallic in darker specimens.  
 Transparency crystals are translucent to transparent.  
 Crystal System is trigonal. 
 Crystal Habits: individual, well formed, large crystals are scarce; crusts and 
crystal complexes are more common; may be massive, or in capillary needles. 
Crystals that are found tend to be the six sided trigonal scalahedrons that appear to 
have opposing three sided pyramids. It also forms modified rhombohedrons, 
prismatic and twinned crystals as discribed above.  
 Cleavage is perfect in three directions, forming prisms.  
 Fracture is uneven to splintery.  
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 Hardness is 2 - 2.5.  
 Specific Gravity is approximately 8.1+ (very heavy for a non-metallic mineral)  
 Streak is red  
 Associated Minerals are realgar, pyrite, dolomite, quartz, stibnite and mercury.  
 Other Characteristics: silghtly sectile and crystals can be striated.  
 Notable Occurances include Almaden, Spain, Idria, Serbia, Hunan Prov., China 
and California, Oregon, Texas, and Arkansas, USA.  
 Best Field Indicators are crystal habit, density, cleavage, softness and color.  
Other forms of cinnabar 
 Hepatic cinnabar is an impure variety from the mines of Idrija in the Carniola 
region of Slovenia, in which the cinnabar is mixed with bituminous and earthy 
matter. 
 Metacinnabarite is a black-colored form of HgS, which crystallizes in the cubic 
form. 
 Synthetic cinnabar is produced by treatment of Hg(II)  
 salts with hydrogen sulfide to precipitate black, synthetic metacinnabarite, which 
is then heated in water. This conversion is promoted by the presence of sodium 
sulfide.  
 Hypercinnabar, crystallise in the hexagonal form. 
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VENKARAM – BORAX   26,27. 
 Borax, also known as sodium borate, sodium tetraborate, or disodium tetraborate, 
is an important boron compound, a mineral, and a salt of boric acid. 
 Chemistry :  Na2B4O7 -10H2O, Hydrated sodium borate.  
 Class  : Carbonates  
 Subclass :  Borates 
Occurrence: 
            Borax is a complex borate mineral that is found in playa lakes and other evaporite 
deposits 
PHYSICAL CHARACTERISTICS: 
 Color is white to clear.  
 Luster is vitreous.  
 Transparency crystals are transparent to translucent.  
 Crystal System is monoclinic. 
 Crystal Habits include the blocky to prismatic crystals with a nearly square cross 
section. Also massive and as crusts.  
 Cleavage is perfect in one direction.  
 Fracture is conchoidal.  
 Hardness is 2 - 2.5  
 Specific Gravity is approximately 1.7 (very light)  
 Streak is white.  
 Associated Minerals are calcite, halite, hanksite, colemanite, ulexite and other 
borates.  
 Other Characteristics: a sweet alkaline taste, alters to chalky white tincalconite 
with dehydration.  
 Notable Occurrences include Trona, Boron, Death Valley and other California 
localities; Andes Mountains; Turkey and Tibet.  
 Best Field Indicators are crystal habit, color, associations, locality, density and 
hardness.  
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Structure: 
 The basic structure of borax contains chains of interlocking BO2(OH) triangles 
and BO3(OH) tetrahedrons bonded to chains of sodium and water octahedrons. Most old 
mineral specimens of borax are chalky white due to a chemical reaction from 
dehydration. They have actually altered (at least on their surface) to the mineral 
tincalconite, Na2 B4O7-5H2O, with the loss of water. This kind of alteration from one 
mineral to another leaves the original shape of the crystal. Minerologists  refer to this as a 
pseudomorph, or "fake shape", because the tincalconite has the crystal shape of the 
predecessing borax.  
 The term  borax  is often used for a number of closely related minerals or 
chemical compounds that differ in their crystal water content. 
 Anhydrous borax (Na2B4O7) 
 Borax pentahydrate (Na2B4O7·5H2O) 
 Borax decahydrate (Na2B4O7·10H2O) 
 Borax is generally described as Na2B4O7·10H2O. However, it is better formulated 
as Na2[B4O5(OH)4]·8H2O, since borax contains the [B4O5(OH)4]2  ion. In this structure, 
there are two four-coordinate boron atoms (two BO4 tetrahedra) and two three-coordinate 
boron atoms (two BO3 triangles). 
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JOURNAL  REVIEW OF SARVA NOI LINGA CHENDURUM 
 
Sarva Noi Linga Chenduram mentioned for lithontriptic activity is composed of 
sulphide of mercury and sodium tetra borate. On the topic of that the following journals 
are reviewed. 
To determine the effect of Linga bhupathi tablets ( Siddha formulation of 
Impcops) on Indian earthworms. Methods: Linga bhupathi (100mg/ tablet) were 
investigated for activity in Indian earthworms (Pheretima postuma) against piperazine 
citrate (15mg/ml) and albendazole (20mg/ml) as standard reference and normal saline as 
control. The time to achieve paralysis of the worms was determined. Results: The two 
concentration of Linga bhupathi tablet exhibited significant anthelminthic activity 
(p<0.001) when compared with the piperazine citrate, albendazole and normal saline. 
Conclusion: Linga bhupathi tablet has paralytic effect on Indian earthworms.1 
Linga kattu has the efficacy to control the fungal growth in lower concentrations2 
The mechanism of action of mercurial diuretics has been analyzed by examining 
32 different organic mercurials and determining their in vitro acid lability, rate of 
excretion, and structural characteristics, and correlating this with their activity as 
diuretics. All active diuretics are acid labile. No acid stable compounds are diuretics. 
However, within the acid labile group, distribution, as reflected by rate of excretion, 
appears to be a second determinant of diuretic potency. The factors which influence 
distribution and excretion are discussed. The urinary excretory products of mercurials 
have been identified. In most instances these are mainly the cysteine complex of the 
administered mercurial. With extremely acid-labile compounds, the urinary excretory 
product may be identified as mercuric cysteine, thus demonstrating the in vivo rupture of 
the carbon-mercury bond. It is concluded that the diuretic response is attributable to the in 
vivo intrarenal release of mercuric ions and that, with the compounds commonly 
employed, this occurs with only a minute fraction of the agent that is administered.Some 
components of mercurial diuretics are given below 3. 
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A study conducted  on female mongrel dogs about  structure diuretic activity 
relationships of organic compounds of mercury. The results showed that the following 
components possess diuretic activity.4 
 3-hydroxy mercuri-2 methoxy -1 propycarbamyl –o-phenoxy acetate. 
 3-acetomercuri-2-methoxy succinyl propyl urea. 
 3-chloromercuri-2-methoxy propyl urea. 
 Aceto mercuric-2-methoxy 1-hydroxy propane. 
 3-bromo mercuric propane. 
 Mercuric chloride. 
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PHYSICAL PROPERTIES 
The physical properties of Sarva Noi Linga Chenduram was carried out in Sri 
Ramachandra University Chennai. 
pH at 10% of aqueous solution: 
Five grams of  the sample weighed accurately and placed in clear 100 ml beaker. 
Then 50 ml of distilled water is added to it and dissolved well. Wait for 30 minutes and 
then apply in to pH meter at standard buffer solution of 4.0, 7.0, 9.2. (trial drug 2 table 3) 
Ash Values: 
The Ash values are a measure of the inorganic constituents present in the raw 
drug.  A high ash content explains its unsuitable nature to be used as a drug (trial drug 2 
table 3) 
Total Ash: 
A little of extract was taken in a silica crucible previously ignited, cooled and 
weighed. It was incinerated by gradually increasing the heat not exceeding dull red heat 
(450°C) until free from carbon, cooled and weighed. The percentage of ash 
was calculated with reference to air- dried drug. The procedure was repeated to get the 
constant weight. (trial drug 2 table 3) 
Water soluble ash: 
The total ash was boiled with 25 ml water and filtered through ash less filter paper 
(Whatmann 4.1). It was followed by washing with hot  water .The  filter paper  was dried  
and ignited in the silica crucible, cooled and the water insoluble ash was weighed.The 
water-soluble ash can be calculated by subtracting the water insoluble ash from the total 
ash. (trial drug 2 table 3) 
Acid insoluble ash: 
The total ash obtained was boiled for 5 minutes with 25 ml of (10% w/v) dilute 
hydrochloric acid and filtering through ash less filter paper (Whatmann 4.1).  The filter 
paper was ignited in the silica crucible, cooled and insoluble ash was weighed. (trial drug 
2 table 3) 
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BIO -CHEMICAL ANALYSIS OF SARVA NOI LINGA CHENDURAM   
 The biochemical analysis of the Sarva Noi Linga Chenduram was carried out in 
the Biochemistry lab, NIS, Chennai. 
S.No EXPERIMENT OBSERVATION INFERENCE 
1.         Appearance of sample Light yellow in 
colour 
 
2. Solubility: 
a. A little(500mg) of the sample 
was shaken well with distilled water. 
b. A little(500mg) of the sample 
was shaken well with con. HCl/Con. 
H2So4 
Sparingly soluble 
 
 
Absence of 
Silicate 
3. Action of Heat: 
   A small amount(500mg) of the 
sample was taken in a dry test tube and 
heated gartly at first and then strong. 
 
 No white fumes 
evolved  
 
 
Absence of 
Carbonate 
 
4. Flame Test: 
  A small amount(500mg) of the sample 
was made into a paste with con. HCl in 
a watch glass and introduced into non-
luminous part of the Bunsen flame. 
 No Bluish green 
flame appeared. 
Absence of Copper 
5. Ash Test: 
   A filter paper was soaked into a 
mixture of sample and dil. cobalt 
nitrate solution and introduced into the 
Bunsen flame and ignited. 
No Yellow colour 
flame appeared. 
Absence of sodium 
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Preparation of Extract: 
5gm of Sarva Noi Linga Chendurum was weighed accurately and placed in a 
250ml clean beaker and added with 50ml of distilled water. Then it was boiled well for 
about 10 minutes. Then it was cooled and filtered in a 100ml volumetric flask and made 
up to 100ml with distilled water. 
S.No EXPERIMENT OBSERVATION INFERENCE 
 I.Test For Acid Radicals   
1.  Test For Sulphate: 
a. 2ml of the above prepared extract 
was taken in a test tube to this added 2ml 
of 4% dil ammonium oxalate solution 
b. 2ml of the above prepared extracts 
was added with 2ml of dil-HCl was added 
until the effervescence ceases off. Then 
2ml of dil.Barium chloride solution was 
added. 
 Cloudy 
appearance present 
 
 
   Presence  
of Sulphate 
 
 
 
2. Test For Chloride: 
  2ml of the above prepared extract was 
added with dil. HCl till the effervescence 
ceases. Then 2ml of dil.silver nitrate 
solution was added. 
No cloudy 
appearance. 
  Absence  
of Chloride 
3. Test For Phosphate: 
  2ml of the extract was treated with 2ml 
of dil.ammonium molybdate solution and 
2ml of con.HNo3. 
 No  Yellow 
appearance present 
   Absence   
of Phosphate 
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4 
.  
Test For Carbonate: 
    2ml of the extract was treated with 2ml 
dil. Magnesium sulphate solution 
No Cloudy 
appearance. 
  Absence  
of carbonate 
5. Test For Nitrate: 
  1gm of the substance was heated with 
copper turning and concentrated H2So4 
and viewed the test tube vertically down. 
 
No Brown gas 
evolved. 
 
   Absence  
of Nitrate 
6. Test For Sulphide: 
  1gm of the substance was treated with 
2ml of con. HCL 
No Rotten Egg 
Smelling gas. 
   Absence  
of Sulphide 
7. Test For Fluoride & Oxalate: 
  2ml of extract was added with 2ml of dil. 
Acetic acid and 2ml dil.calcium chloride 
solution and heated. 
No Cloudy 
appearance 
      Absence  
of fluoride and 
oxalate 
8. Test For Nitrite: 
  3drops of the extract was placed on a 
filter paper, on that-2 drops of dil.acetic 
acid and 2 drops of dil.Benzidine solution 
was placed. 
No Characteristic 
changes 
   Absence  
of Nitrite 
9. Test For Borate: 
  2 Pinches(50mg) of the substance was 
made into paste by using dil.sulphuric 
acid and alcohol (95%) and introduced 
into the blue flame. 
 
 Bluish green 
colour flame. 
   presence  
of borate 
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 II. Test For Basic Radicals   
1. Test For Lead: 
        2ml of the extract was added with 
2ml of dil.potassium iodine solution. 
No yellow 
Precipitate 
obtained. 
Absence of Lead 
2. Test For Copper: 
a. One pinch(50mg) of substance 
was made into paste with con. HClin a 
watch glass and introduced into the non-
luminuous part of the flame. 
No Blue colour 
flame 
No Blue colour 
precipitate formed. 
 
  Absence  
of copper 
 
 
3. Test For Aluminium: 
  To the 2ml of extract, dil.sodium 
hydroxide was added in 5 drops to excess. 
NoYellow colour 
appeared. 
   Absence   
of aluminium 
4. Test For Iron: 
a. To the 2ml of extract,2ml of 
dil.ammonium solution was added. 
b. To the 2ml of extract 2ml  
thiocyanate solution and 2ml  of con 
HNo3 was added 
 
No blood red 
colour appeared. 
 
 
 
Absence of Iron 
 
 
5. Test For Zinc:  
      To 2ml of the extract, dil.sodium 
hydroxide solution was added in 5 drops 
to excess and dil.ammonium chloride was 
added.  
 
No White 
precipitate was  
formed 
 
Absence of Zinc 
6. Test For Calcium:  
      2ml of the extract was added with 2ml 
of 4% dil.ammonium oxalate solution  
 No Cloudy 
appearance and 
white precipitate 
was obtained 
 
   Absence  
of calcium 
74 
 
7. Test For Magnesium:  
         To 2ml of extract dil.sodium 
hydroxide solution was added in drops to 
excess. 
 
No white 
precipitate was  
obtained 
 
   Absence  
of Magnesium 
8. Test For Ammonium: 
  To 2ml of extract 1 ml of Nessler's 
reagent and excess of dil.sodium 
hydroxide solution are added. 
 
  No Brown colour 
appeared 
 
     Absence  
 of ammonium 
9. Test For Potassium:  
   A pinch(25mg) of substance was treated 
of with 2ml of dil.sodium nitrite solution 
and then treated with 2ml of dil.cobalt 
nitrate in 30% dil.glacial acetic acid. 
 
No Yellowish 
precipitate was 
obtained. 
 
   Absence  
of Potassium 
10. Test For Sodium: 
    2 pinches(50mg) of the substance was 
made into paste by using HCl and 
introduced into the blue flame of Bunsen 
burner. 
  No yellow colour 
flame appeared 
    Absence  
of sodium 
11. Test For Mercury:  
   2ml of the extract was treated with 2ml 
of dil.sodium hydroxide solution.  
No yellow 
precipitate was 
obtained 
   Absence  
of mercury 
12. Test For Arsenic:  
   2ml of the extract was treated with 2ml 
of dil.sodium hydroxide solution. 
 
No brownwish red 
precipitate was 
obtained 
 
    Absence  
of arsenic 
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 III. Miscellaneous   
1.
  
Test For Starch:  
  2ml of extract was treated with weak 
dil.iodine solution  
 
No  blue colour 
developed 
 
      absence  
of starch 
2.
  
Test For Reducing Sugar:  
    5ml of Benedict's qualitative solution 
was taken in a test tube and allowed to 
boil for 2 minutes and added 8 to 10 drops 
of the extract and again boil it for 2 
minutes. The colour changes are noted. 
 
Brick red colour 
not developed 
 
   Absence of  
reducing sugar 
3.
  
Test For The Alkaloids: 
a) 2ml of the extract was treated with  2ml 
of dil.potassium iodide solution. 
b)  2ml of the extract was treated with  
2ml of dil.picric acid. 
c)  2ml of the extract was treated with 2ml 
of dil.phosphotungstic acid. 
 
. 
  
No Yellow colour 
developed 
 
- 
 
   Absence  
of Alkaloid 
s4.
  
Test For Tannic Acid:  
  2ml of extract was treated with 2ml of 
dil.ferric chloride solution  
  black precipitate 
was obtained 
    Absence  
of Tannic acid 
5.
  
Test For Unsaturated Compound: 
  To the 2ml of extract 2ml of 
dil.Potassium permanganate solution was 
added.  
 
 
Potassium 
permanganate was 
not decolourised 
 
     Absence  
of unsaturated 
compound  
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6.
  
Test For Amino Acid: 
    2 drops of the extract was placed on a 
filter paper and dried well. 20ml of  
Biurette reagent was added. 
 
No violet colour 
developed 
 
   Absence  
of amino acids 
7. Test For Type Of Compound: 
    2ml of the extract was treated with 2 ml 
of dil.ferric chloride solution.  No green colour 
developed 
 
 
No red colour 
developed 
 
 
 
No violet colour 
developed 
 
No blue colour 
developed 
Absence of oxy 
quinole 
pinephrine and 
pyro catechol 
Anti pyrine, 
Aliphatic amino 
acids and 
meconic  
acid are absent  
Apomorphine 
salicylate and 
Resorcinol are 
absent 
Morphine, 
Phenol cresol 
and hydro 
uinone are 
absent 
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ATOMIC ABSORBTION SPECTROSCOPY 
Atomic Absorbtion Spectroscopy of Sarva Noi Linga Chenduram was carried out 
in Sri Ramachandra University, Chennai 
The elemental analysis of digested samples have been determined by Atomic 
Absorption Spectrophotometer (AAS model 400 Perkin Elmer).  In this method the 
sample, in the form of a homogeneous liquid, is introduced into a flame where thermal 
and chemical reactions create “free” atoms capable of absorbing, emitting or fluorescing 
at characteristic wavelengths.   
In Atomic Absorption Spectrophotometer (AAS) the majority of free atoms in the 
commonly used flames were in the ground state, but that the flames did not also have 
enough energy to excite these atoms.  A light source emitting a narrow spectral line of the 
characteristic energy is used to excite the free atoms formed in the flame.  The decrease in 
energy (absorption) is then measured. 
METHODOLOGY  
I. Microwave Digestion For Elemental Analysis 
Model Name: Multiwave3000 
Digestion Procedure: 
200mg of the given sample is placed in a digestion vessel, acid is added and the 
mixture is heated for several minutes. After the digestion, the samples are diluted to a 
specific volume. If too much sample is used in wet digestion, the reaction mixture can 
become violent. The samples are placed in digestion vessels that fit directly into digestion 
racks. There are several different acids or mixtures of acids used for digestion, the most 
common of which is concentrated Hydrochloric acid. The samples are heated slowly at a 
high temperature. After digestion, the samples are diluted to the appropriate volume with 
deionized H2O.  
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II. Elemental Analysis using Atomic Absorption Spectrophotometer 
The elemental analysis of digested samples have been determined by Atomic 
Absorption Spectrophotometer- Flame technique (AAS model 400 Perkin Elmer). 
Working standard solutions of sulphur, borate, mercury  were prepared from stock 
standard solution of 1000 ppm from MERCK.  Using blank solution to zero the 
instrument performs the Calibration.  The standards are then analyzed and their 
absorbance recorded. A graph of Absorbance Vs Concentration is plotted. Calibration of 
the instrument was repeated periodically during operation.  A blank reading was also 
taken and necessary correction was made during the calculation of concentration of 
various elements. 
The digested material was made upto 100 ml for analysis in an (AAS) atomic 
absorption spectrophotometer (Perkin Elmer). The results were calibrated using standard 
calibration curve. 
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ACUTE AND SUB ACUTE TOXICITY STUDIES  ON SARVA NOI LINGA 
CHENDURAM  IN RODENTS 
Animals:  
 Mice of either sex weighing 25-30g and rats weighing 210-240g were obtained 
from the animal house of Vels University. The animals were used with the approval of the 
Institute animal ethics committee and obtained from Vels University, Chennai. They were 
fed with a balanced standard pellet diet and maintained under standard laboratory 
conditions, providing 24-280C temperature, standard light cycle (12 h light, 12 h dark) 
and water ad libitum. Animals were kept in cages with raised floors of wide mesh to 
prevent coprophagy. Animal welfare guidelines were observed during the maintenance 
period and experimentation. The rats were randomly assigned to control and different 
treatment groups, six animals per group. (Approval number: 
XIII/VELS/PCOL/36/2000/CPCSEA/IAEC/08.08.2012). The animals were acclimatized 
for one week under laboratory conditions.  
ACUTE TOXICITY STUDY-OECD 425 GUIDELINES 
 Acute oral toxicity test for the Sarva Noi Linga Chenduram was carried out as per 
OECD Guidelines 425. As with other sequential test designs, care was taken to ensure 
that animals are available in the appropriate size and age range for the entire study. The 
test substance is administered in a single dose by gavage using a stomach tube or a 
suitable intubation cannula. The fasted body weight of each animal is determined and the 
dose is calculated according to the body weight. After the substance has been 
administered, food was withheld for a further 2 hours in mice. The animals were observed 
continuously for the first 4 h and then each hour for the next 24 h and at 6 hourly intervals 
for the following 48 h after administering of the test drug, to observe any death or 
changes in general behaviour and other physiological activities. Single animals are dosed 
in sequence usually at 48 h intervals. However, the time interval between dosing is 
determined by the onset, duration, and severity of toxic signs. Treatment of an animal at 
the next dose was delayed until one is confident of survival of the previously dosed 
animal.  
80 
 
Observation of toxicity signs: General behavior, respiratory pattern, cardiovascular signs, 
motor activities, reflexes, change in skin and fur, mortality and the body weight changes 
were monitored daily. The time of onset, intensity, and duration of these signs, if any, was 
recorded.  
SUB-ACUTE TOXICITY  
 In a 28-days sub acute toxicity study, twenty four either sex rats were divided into 
four groups of 6 rats each. Group I that served as normal control was administered with 
distilled water (p.o.) while groups II, III and IV were administered daily with the Sarva 
Noi Linga Chenduram (p.o.) for 28 days at a dose of 50,100,200 mg/kg respectively. The 
animals were then observed daily for gross behavioural changes and any other signs of 
subacute toxicity. The weight of each rat was recorded on day 0 and weekly throughout 
the course of the study, food and water consumption per rat was calculated. At the end of 
the 28 days they were fasted overnight, each animal was anaesthetized with diethylether, 
following which they were then dissected and blood samples were obtained by cardiac 
puncture into heparinised tubes. The blood sample collected from each rat was 
centrifuged with 3000 X g at 4oC for 10 min to separate the serum and used for the 
biochemical assays.  
Hematological and blood biochemical analyses:  
 At the end of the study, all animals were kept fasted for 16-18 h and then 
anesthetized with anesthetic ether on the 28th day. Blood samples for hematological and 
blood chemical analyses were taken from retro orbital vein. Heparinized blood samples 
were taken for determining complete blood count (white blood cell count, differential 
white blood cell count, platelet count, red blood cell count, hematocrit, and hemoglobin) 
by semiautomated hematology analyzer. The serum from non-heparinized blood was 
carefully collected for blood chemistry and enzyme analysis (glucose, blood urea nitrogen 
(BUN), creatinine, total protein, albumin, total and direct bilirubins, serum glutamate-
oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), and 
alkaline phosphatase (ALP)) were automatically determined using autoanalyzer. 
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Necropsy:  
 All rats were sacrificed after the blood collection. The positions, shapes, sizes and 
colors of internal organs were evaluated. The Spleen, Testes, Pancreas, Lungs, Liver, 
Brain, Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were excised from all 
rats to visually detect gross lesions, and weighed to determine relative organs’ weights 
and preserved in 10% neutral formalin for histopathological assessment. The tissues were 
embedded in paraffin, and then sectioned, stained with haematoxylin and eosin and were 
examined microscopically. 
Statistical analysis 
 Values were represented as mean ± SEM. Data were analysed using one-way 
analysis of variance (ANOVA) and group means were compared using the Tukey-Kramer 
Multiple Comparisms Test using GraphPad Instat-V3 software. P values < 0.05 were 
considered significant. (trial drug 2  table 5-14 ) 
RESULTS AND DISCUSSION 
 In acute toxicity study, the animals treated with 1000mg/kg were showed 
tolerance with negligible toxic signs. Hence the one tenth of the dose was selected as 
median therapeutic dose for the further study. In sub acute toxicity study, animals were 
shown significant toxic clinical signs during the dosing period of 28 days. Animals from 
Sarva Noi Linga Chenduram treated dose groups not survived throughout the dosing 
period of 28 days and it was found two animals dead after 12days of treatment in high 
dose. Results of body weight determination of animals of control and different dose 
groups exhibited reduction in body weight (P>0.05) after one week of the dosing period.  
 During dosing period, the quantity of food consumed by animals from different 
dose groups was found to be comparable (P>0.05) and normal with that of control 
animals. Ophthalmoscopic examination of animals in control and Sarva Noi Linga 
Chenduram treated group revealed abnormality as liver damage. Urine analysis data of 
control group and Sarva Noi Linga Chenduram treated group of animals determined 
revealed abnormalities like increase in urine volume and colour was reddish brown. Gross 
pathological examination of animals in control as well as the Sarva Noi Linga Chenduram 
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treated group revealed abnormalities like liver damage at higher dose treated animals and 
also and microanatomical changes in bone and spleen tissue.  
 The results of haematological investigations, revealed mild changes (P>0.05) 
when compared with those of respective controls. Results of Biochemical investigations 
conducted on days 28 revealed the significant changes in the values of different 
parameters when compared with those of respective controls. Globulin showed increased 
levels in animals in 50mg/kg dose group (P<0.01), Total Protein level is elevated in 
animals of 100 and 200mg/kg dose group but it is statistically not significant. Uric acid 
level was elevated in animals of 50 and 200mg/kg group (P<0.05). Other all biochemical 
and Haematological parameters were found to be within normal limit as compared to 
control group values. 
CONCLUSION 
 Toxic effect was observed at 200mg/kg of Sarva Noi Linga Chenduram treated via 
oral route over a period of 28 days. So, it can be concluded that the Sarva Noi Linga 
Chenduram can be prescribed for therapeutic use in human with the dosage 
recommendations of upto maximum of 100mg/kg body weight p.o. for long term 
administrations the 20-30% of dose reduction is very essential to avoid organ damage. 
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HISTO-PATHOLOGICAL SLIDES – TOXICITY STUDIES  
FOR TRIAL DRUG 2 
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LITHONTRIPTIC  ACTIVITY OF SARVA NOI  LINGA CHENDURAM IN 
ETHYLENE GLYCOL INDUCED LITHIATIC RATS 
AIM 
To evaluate the Lithontriptic  activity  of  Sarva Noi Linga Chenduram in ethylene 
glycol induced lithiatic rats. 
MATERIALS AND METHODS 
Preparation of drug and stock solution 
The suspension of siddha drug Sarva Noi Linga Chenduram in 2% (w/v) CMC 
was prepared for oral administration by gastric intubation method. 
Animal selection 
 For acute toxicity studies, Wistar albino mice of either sex weighing between 28 
and 30 g were selected. For the antiurolithiatic study, male Wistar weighing between 180-
220 g were used. The animals were acclimatized to standard laboratory conditions 
(temperature: 25±2°C) and maintained on 12-h light: 12-h dark cycle.  They were 
provided with regular rat chow and drinking water ad libitum. 
 (Approval numberXIII/VELS/PCOL/37/2000/CPCSEA/IAEC/08.08.2012). 
Acute toxicity studies 
 The acute oral toxicity study was carried out as per the OECD guidelines 425. 
One-tenth of the median lethal dose was taken as an effective dose. 
Ethylene glycol induced urolithiasis model 
 Ethylene glycol induced urolithiatic model in rat was be used to assess the effect 
of Sarva Noi Linga Chenduram. The study is designed to find out the effect of Sarva Noi 
Linga Chenduram on therapeutic usage against ethylene glycol induced urolithiasis. All 
rats were housed in metabolic cages for entire duration of the experiment. Animals were 
divided into five groups containing six animals in each.  Group I served as control and 
received regular rat food and drinking water ad libitum. Ethylene glycol (0.75%) in 
drinking water was fed to Groups II-V for induction of renal calculi till 28th day.  Group 
II received Ethylene glycol alone and served as urolithiatic control. Group III received 
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standard antiurolithiatic drug, cystone (750mg/kg body weight) from 15th day till 28th day.  
Groups IV received Sarva Noi Linga Chenduram (50mg/kg body weight) from 15th day 
till 28th day, Group V received Sarva Noi Linga Chenduram (100mg/kg body weight) 
from 15st day till 28th day.   
Group and Treatment 
Group 1: Treated with Normal saline 
Group 2: Treated with Control (ethylene glycol) + vehicle 
Group 3: Treated with Standard (ethylene glycol + Cystone) 
Group 4: Treated with Sarva Noi Linga Chenduram (50mg/kg) + ethylene glycol 
Group 5: Treated with Sarva Noi Linga Chenduram (100mg/kg) + ethylene glycol 
All doses were given once daily by oral route. 
Assessment of lithontriptic activity 
Collection and analysis of urine: 
 All animals were kept in individual metabolic cages and urine samples of 24h 
were collected on 28th day.  Animals will be having free access to drinking water during 
the urine collection period.  A drop of concentrated hydrochloric acid was added to the 
urine before being stored at 4°C.  Urine was analyzed for calcium, phosphate and oxalate 
content. 
Serum Analysis: 
 After the experimental period, blood was collected from the retro-orbital vein 
under anesthetic conditions and animals were sacrificed by cervical decapitation.  Serum 
was separated by centrifugation at 10,000x g for 10 min and analyzed for creatinine, uric 
acid and urea nitrogen. 
Kidney homogenate analysis: 
 The abdomen was cut open to remove both kidneys form each animal.  Isolated 
kidneys were cleaned off extraneous tissue and preserved in 10% neutral formalin.  The 
kidneys were dried at 80°C in a hot air oven.  A sample of 100mg of the dried kidney 
were boiled in 10ml of 1N hydrochloric acid for 30min and homogenized.  The 
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homogenate was centrifuged at 2000x g for 10min and the supernatant was separated.  
The calcium, phosphate and oxalate content in kidney homogenate were determined. 
DIURETIC ACTIVITY: 
Standarsization Of Furosemide   
 Seven groups of six male wistar albino rats were employed four doses of 
10,15,20,25-mg/kg b.w of furosemide were administered intraperitonealy to each group 
of rats separately.  The control animals received normal saline alone. The animals were 
placed in separate cages and the urine output over 24hr period was collected. This 
procedure was repeated. The most consistent dose (15mg/kg b.w) was adapted for dosing.  
Evaluation of diuretic activity 
 Five groups of six male Wistar albino rats were used. First group received normal 
saline.  Second group received Sarva Noi Linga Chenduram 50mg/kg.  The third group 
received Sarva Noi Linga Chenduram 100mg/kg.  The fourth group was administered 
furosemide 20mg/kg.  Immediately after administration of the drug, the rats were placed 
in metabolic cages, specially designed to separate urine and feacal matter and was 
observed at room temperature. The animals were denied for food and water during the 
experiment. The urine volume (ml/day) was measured and then assayed for Na+ and K+ 
and Cl- concentrations in mMol/l, Cl was measured using routine method. 
Statistical analysis: 
 Results expressed as mean ± S.E.M.  Differences among data was determined 
using one-way ANOVA followed by Dunnet ‘t’ test. (trial drug 2 table 14-18 bar diagram 
1-4) 
RESULTS AND DISCUSSION 
 The results of acute toxicity study revealed that the Sarva Noi Linga Chenduram 
is tolerable upto 1000mg/kg and the therapeutic dose was fixed as 50 and 100mg/kg for 
further pharmacological investigation. Ethylene glycol induced urolithiasis resulted in 
significant elevation of urine volume, kidney calcium, oxalate, inorganic phosphate, 
serum blood urea nitrogen, creatinine and uric acid compared to normal control group. 
Treatment with cystone (750 mg/kg) and Sarva Noi linga Chenduram reduced the bio-
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chemical changes induced by ethylene glycol. In order to probe the possible mechanism 
by which Sarva Noi Linga Chenduram cures renal damage caused by ethylene glycol, 
investigation on levels of various stone inhibitors like total protein, magnesium and 
citrate was studied. There was significant rise on total protein, magnesium and citrate 
after treatment with cystone and Sarva Noi Linga Chendooram.  
 Administration of ethylene glycol significantly reduced the body weight, urine 
volume and pH of urine as compared to normal group. Rats treated with cystone and 
Sarva Noi Linga Chenduram also showed significant decreased in body weight, urine 
volume and pH of urine as compared to control group. The histopathological study of the 
kidney sections also supported the above results. In all the stone forming rats there was 
damage to the last part of the nephron, collecting system and peritubular interstitium as 
compared to the normal rat kidney architecture. The tubules appeared focally ecstatic and 
surrounded by inflammatory infiltration.  
 Flattened epithelium with focal vacuolar degeneration and single cell necrosis 
bordered the tubules, which focally contained hyaline casts. Inflammatory infiltration was 
mainly composed of mature lymphocytes infiltrating tubular epithelium. Irregular crystals 
were present inside the tubules and in the peritubular interstitium, along the nephron and 
at papillary level. The Sarva Noi Linga Chenduram treated groups showed normal 
histology of the kidney, and shows normal glomeruli, slight oedema of the tubular cells 
compared to standard drug treated animals. The kidneys excised from ethylene glycol 
treated group were larger and heavier than from the control animals. When observed 
under light microscope, many crystalline deposits in the histological preparations were 
seen in tubules of all regions of kidney.  
 In Sarva Noi Linga Chenduram along with EG treated rats, such deposits were 
small and less abundant. Microscopic examination of kidney sections derived from EG 
induced urolithiatic rats showed calcification inside the tubules which causes dilation of 
the proximal tubules. Co-treatment with Sarva Noi Linga Chenduram decreased the 
calcification in different parts of the renal tubules and also prevented damages to the 
tubules and calyxes. Organ-body weight ratio is a marker of cell constriction and 
inflammation. The non-significant effect on the rat kidney-body weight ratio following 
the administration of various doses of the Sarva Noi Linga Chenduram suggests that the 
drug did not induce inflammation or constriction of the kidney cells.  
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 Pathologic studies have shown that the renal failure from EG is associated with 
proximal tubule cell necrosis leading to production of several metabolites (glycol 
aldehyde, glycolate, glyoxylate and oxalate, in that order) and accumulation of large 
calcium oxalate monohydrate crystals in tubular lumen.  
 An Ayurvedic compound preparation (Cystone) was found to contain water 
soluble substances, which inhibited the initial precipitation of calcium and phosphate ions 
in the form of a mineral phase bound to the organic matrix and the subsequent growth of 
the preformed mineral phase. In the present study, concurrent administration of EG with 
cystone/ Sarva Noi Linga Chenduram causes significant curative effect in EG induced 
changes. The effect is dose dependent. The effectiveness of Sarva Noi Linga Chenduram 
is comparable to cystone.  
  The architectural appearance of the kidneys from the rats in the control group, 
presented a normal histological appearance with no calcium oxalate depositions with 
normal glomeruli, tubules surrounded by the Bowmanís capsule, proximal and distal 
convoluted tubules without any inflammatory changes and normal blood vessels. On the 
other hand, disrupted renal parenchyma showing loss of structural arrangement of renal 
tubules, early degenerative changes in glomeruli and focal calcification in glomerulo-
tubular structures and congested blood vessels were observed in the renal tissue of 
urolithiatic rats.  
 The renal tissue of EG along with Sarva Noi Linga Chenduram shows only few 
stray areas of calcification in glomeruli and normal tubular structures with no congestion 
in blood vessels. The renal tissue of standard drug treatment still shows moderate 
calcification in many tubules and few glomeruli. It has been reported that the kidneys are 
the principle target organ for ethylene glycol toxicity and administration of ethylene 
glycol for 3 weeks resulted in insignificant urinary oxalate excretion and deposition of 
crystals in kidney, hence in our study ethylene glycol was chosen to induce lithiasis. 
Following the induction of lithiasis the urinary volume and composition were found to be 
altered.  
 In our study also the urinary output was markedly decreased in lithiatic control 
rats on day 28, however in Sarva Noi Linga Chenduram and standard treated rats the 
urinary volumes were increased when compared to that lithiatic Group. This suggested 
that Sarva Noi Linga Chenduram might have moderate diuretic effect. Following ethylene 
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glycol administration the excretion of calcium, oxalate, phosphate and protein were found 
to be increased in lithiatic group while in standard, test groups these levels were 
significantly decreased (P<0.01).  
 On contrary to this the magnesium level was decreased in lithiatic group while in 
standard and Sarva Noi Linga Chenduram treated groups those levels were increased 
significantly (P<0.01). The serum creatinine levels of Sarva Noi Linga Chenduram 
treated rats restored to normal limits and the creatinine clearance was also found to be 
improved. The findings of the histopathological studies suggested that no microcrystalline 
deposition and kidney damage in the Sarva Noi Linga Chenduram treated groups. All 
these observations enabled us to confirm the inhibitory potential of Sarva Noi Linga 
Chenduram on ethylene glycol induced lithiasis. 
CONCLUSION  
 The presented data indicate that administration of the Sarva Noi Linga Chenduram 
to rats with ethylene glycol induced lithiasis reduced the formation of urinary stones, 
regarding lithontriptic  activity of the Sarva Noi Linga Chenduram. The mechanism 
underlying this effect is still unknown, but is apparently related to diuresis and lowering 
of urinary concentrations of stone forming constituents. These effects could conclude the 
antiurolithiatic property of Sarva Noi Linga Chenduram. 
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HISTO-PATHOLOGICAL SLIDES –  PHARMACOLOGICAL 
STUDIES  FOR TRIAL DRUG 2 
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Standard cystone. 
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SIDDHA ASPECT 
¸øÄ¨¼ôÒ §¿¡ö28 
 
  
§ÅÚ ¦ÀÂ÷: 
             «îºÁÃ¢ 
 
 
ÂøÒ: 
 
º¢Ú¿£÷ ¸Æ¢ìÌí¸¡ø « Ð Èí¸¢ì ¦¸¡ñÊÕìÌõ§À¡§¾ ¾¢Ë¦ÃÉ 
¿£Ã¨¼ò¾ø,ÌÈ¢Ó¨É §¿¡¾ø,¿£÷ôÒ¨Æ ±Ã¢¾ø, ÎôÀ¢ý À¢ýÒÚòÐõ, ÓÐÌò 
¾ñÊý Àì¸òÐõ §¿¡¾ø,º¢Ú¿£÷¢ø Á½¨Ä¦Â¡ò¾ º¢Ú ¸ü¸û  ¸Äó¾¢Õò¾ø ¬¸¢Â 
¾ý¨Á¸¨ Ô¨¼Â¾¡õ. 
 
§¿¡ö ÅÕõ ÅÆ¢ :  
 
 
    Í¨É ¿£÷ ÀýÉ¡ð¸û §¾í¸¢Â ¿£÷ ¨Å¸¨ ô ÀÕÌÅ¾¡Öõ, Á¡ôÀñ¼õ, 
Å ¢ìÌüÈò¨¾ Á¢Ì¾¢ôÀÎòÐõ ¯½× Ó¾Ä¢ÂÅü¨È ¯ñÀ¾¡Öõ Å¢óÐ 
¸ðÎôÀÎÅ¾¡Öõ ó§¿¡ö À¢ÈìÌõ ±Éì ÜÚÅ÷. 
 
           "¸Äí¸¢É§¾¡÷ ¾ñ½£÷¾ý ÌÊò¾ §À÷ìÌì 
                   ¸ø¦ÄÖõÒ ÁÂ¢÷Áñ¾¡ý ¸Äó¾ý Éò¾¢ø 
            «Äí¸¢Â§¾¡ ÃýÉí¸ Õó¾ Ä¡Öõ 
                   «Õ¸¦Ä¡Î ÀÆõÀñ¼ ÁÕó¾ Ä¡Öõ 
             ÁÄí¸¢É§¾¡÷ Á¡ôÀñ¼ ÁÕó¾ Ä¡Öõ 
                    Áó¾ò¾¢ø Å¡ÔÅ¡õ À¾¡÷ò¾ó ¾ý¨Éò 
             ÐÄí¸¢É§¾¡ Õº¢¾ýÉ¢ü Í¨Åò¾ Ä¡Öõ 
                    ÍÕì¸¡öì¸ø Ä¨¼ôÒÅóÐ §¾¡ýÚó ¾¡§É" 
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Å¨¸¸û: 
 
Å ¢  ¸øÄ¨¼ôÒ: 
 
 
       Å ¢ìÌüÈò¾¡ø À¢Èó¾ ¸øÄ¨¼ôÒ §¿¡Â¢ø ¯ó¾¢ìÌì¸£ú,ÍÕìÌ, 
ÍÕì¦¸Éì Ìò¾¨Ä ¯ñ¼¡ì¸¢ ¿£÷ ÈíÌí¸¡ø, ¿¢ýÚ  ¿¢ýÚ ÈíÌõ. ¬ñ 
ÌÈ¢ ¾¡í¸ ÓÊÂ¡¾ ÅÄ¢Ô¼ý,Å£í¸¢ì¸¡Ïõ. «ùÅÄ¢Â¢É¡ø ¯ð¸¡Ã ÓÊÂ¡Áø 
ÐýÀÓñ¼¡¾ÖÁýÈ,¢ «ùÅÄ¢¨Âò ¾¡í¸ ÓÊÂ¡Áø «Ø¾ø ¦ÀÕãîÍÅ¢¼ø 
ÅÂ¢ÚôÀø Ó¾Ä¢ÂÅü¨Èô À¢ÈôÀ¢ìÌõ . ¿£Ã¢ø ¿£÷ôÒ¨ÆÂ¢ý ¦ÁøÄ¢Â ºù×õ 
¦Å ¢Â¡Ìõ. 
 
«Æø ¸øÄ¨¼ôÒ: 
¿£÷ôÒ¨ÆÂ¢ø Õõ¨Àì¸¡öîº¢î Íð¼Ðô §À¡ø ±Ã¢îº¨Ä 
¯ñ¼¡ìÌõ.«ýÈ¢Ôõ , ¯¼ø ÓüÚõ «ÉÄ¡¸  Õò¾Öõ, º¢Ú¿£Õ¼ý ÌÕ¾¢ 
Á¢¸×õ ¦Å ¢ôÀÎ¾Öõ ¿£÷ôÒ¨Æ ÓØÅÐõ Ì¨¼ÅÐ §À¡Öõ, ÌòÐÅÐ§À¡Öõ, 
Üî¦ºÈ¢¾ø §À¡Öõ ,ÅÄ¢ò¾ÖÁ¡É ÌÈ¢Ì½í¸¨ ì ¸¡ðÊ ¿£Ã¢Æ¢Ôõ §À¡Ð 
¦ºó¿¢ÈÁ¡É º¢Ú¸ü¸û ¦Å ¢Â¡Ìõ. 
³Âì ¸øÄ¨¼ôÒ: 
¦¸¡ôâÆ¢§Ä Å¢ø§À¡ø ¿¢Á¢÷óÐ Ìò¾¨Ä ¯ñ¼¡ì¸¢, ÎôÒ, ¦¾¡¨¼ 
¨Å¸¨  Ì¨¼Ôõ .¬ñ ÌÈ¢ Å¢ÚÅ¢ÚòÐì ¸ÎìÌõ. «íÌ 
Å¢Â÷¨ÅÔñ¼¡õ.¦Åñ¨Á ¿¢ÈÓ¨¼Â º¢Ú¸ü¸û º¢Ú¿£Õ¼ý  ¦Å ¢Â¡Ìõ. 
ÓìÌüÈ ¸øÄ¨¼ôÒ : 
               ¿£÷ò¾¡¨ÃÂ¢ø «ÊôÀì¸ò¾¢ø ¾¡í¸ ÓÊÂ¡¾ ÅÄ¢Ôõ, ¿£÷ Å¢ðÎ Å¢ðÎ  
ÅÕ¾Öõ , «¾¢ø ¿¡¦ ¡ýÚìÌì ¨¸ó¿¢¨ÈÂ ×   º¢ÚÁ½ø §À¡ýÈ ¸ü¸û 
¦Å ¢Â¡¾Öõ,«¾Û¼ý ¦Åñ½£÷(Íì¸¢Äõ) ¸º¢ÅÐõ ¬¸¢ÂÌÈ¢ Ì½í¸¨ ì 
¸¡ðÎõ. 
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MODERN   ASPECT 
RENAL CALCULI29 
 Renal calculi are formed when the concentration of certain minerals in the urine 
like phosphorous, calcium, magnesium, uric acid, oxalate or xanthine become too high 
resulting in a build-up of crystals (which are normally flushed out of the system during 
urination) in the urinary tract.   
Synonyms: 
 Renal stone, Kidney stone, Renal calculi, Calculus, Urolithiasis. 
AETIOLOGY 
o Hyperexcretion of relatively insoluble urinary constituents. 
o Physiological changes in urine . 
o Altered urinary crystalloids and colloids.  
o Decreased urinary output of citrate. 
o Vitamin A deficiency. 
o Urinary infection. 
o Urinary stasis. 
o Hyperparathyroidism. 
O Prolonged immobilization. 
o Deficient intestinal colonization of  Oxalobacter formigenes . 
 
PREVALENCE AND INCIDENCE: 
 
It is estimated that at least 10% of the population in the industrialized part of the 
world is afflicted by urinary tract stone disease. 
 
Kidney stones are common in industrialized nations with an annual incidence of 
0.5% to 1.9%. 
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SYMPTOMS: 
 
 Pain is the leading symptom in 75% of cases. 
 Fixed renal pain is located in the kidney region. 
 Urteric colic is an agonizing pain passing from loin to the groin; 
coming on suddenly causing the patient to draw up his knees and 
roll about. It is often accompanied by vomiting and profuse 
sweating. 
 Strangury is the passage of few drops of urine often blood stained 
after painful straining.  
 Ureteric colic is often due to the stone entering the ureters. Also, it 
occurs when the stone is in the renal pelvis and temporarily blocks 
the passage of urine. 
 Blood in urine (Heamaturia) is sometimes a leading and only 
symptom. It can occur during or after an attack of pain. Pyuria, 
which is infection of the kidney with pus in the urine, can also 
occur.  
PHYSICAL SIGNS 
(a)   Tenderness at the 'renal angle' posteriorly.  
(b)  Muscle rigidity over the kidney 
(c)   Swelling in the flank when there is hydronephrosis or pyonephrosis 
associated with renal calculus. 
(d)  Abdominal distension and diminished peristalsis may accompany ureteric 
colic. 
TYPES OF RENAL CALCULI 
      Basically the renal stones can be divided into two major groups 
I. Primary stones  
Ii. Secondary stones. 
(i) PRIMARY STONES  
They appear in apparently healthy urinary tract without any antecedent 
inflammation. 
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(a)   Calcium oxalate 
(b)  Uric acid calculi 
(c)   Cystine calculi 
(d)  Xanthine calculi 
SECONDARY STONES: 
They are usually formed as the result of inflammation. 
(a) Triple phosphate 
 
INVESTIGATIONS 
(a)   Blood examination 
(b)  Urinalysis 
(c)   Radiography -X-ray KUB 
(d)  Ultrasonography 
(e)   Computed tomography 
(g)  Cystoscopy 
(h)  Stone analysis 
DIETARY MEASURES: 
             Fluid intake should be high at all times(5-6) litres. 
Plantain pith juice to be taken. 
Tender coconut water. 
Foods not to be taken: 
Milk. 
Eggs. 
Tomatoes. 
Cauliflower. 
Cabbage. Chicken.,meat, fish 
97 
 
CLINICAL STUDY 
Clinical trial on  Sarva  Noi Linga Chenduram  in the management of  
Kalladaippu (Renal calculi)  for Lithontriptic activity got approved by institutional  
ethical committee, NIS on 24/12/2011. Approval no is NIS/IEC/2011/3/13a-24/12/2011. 
 
Based on the protocol approved by IEC, NIS the study was conducted on 
Kalladaippu (Renal calculi) patients. 
The study was conducted in National Institute of Siddha , Ayothidass  Pandithar 
hospital, . Chennai -47. 
Study type  :          pilot study 
Sample size :  20 patients  
SUBJECT SELECTION 
Patients reporting at OPD of Ayothidoss Pandithar hospital with  inclusion criteria 
were subjected to screening test & documented using screening proforma. 
INCLUSION CRITERIA: 
 Age  :  16-80 years 
 Sex  :  male and female 
 Weight :  45-85 kg 
Symptoms: 
 Colicky pain from loin to groin 
 Burning micturition 
 Frequency of micturition 
 Dysuria 
 Vomiting 
 Nausea 
 Fever 
 Heamaturia 
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Any of 4 clinical symptoms 
Patients  who are willing to undergo X-ray KUB/U.S.G abdomen, haematological  
and urine investigations before and after treatment  
Patients who are willing to attend OPD once in 7 days.  
EXCLUSION CRITERIA: 
 Renal failure  
 Liver disorder 
 Pregnancy and lactation 
 Any other serious illness 
WITHDRAWL CRITERIA: 
 Development of any adverse reaction 
 Occurrence of any other serious illness 
 Non-co-operation of the patient 
 
Trial drug       :   Sarva  Noi Linga Chenduram. 
          
Dose             : 130 mg twice daily after food. 
 
Vehicle           :  Mullangi (Raphanus sativus) juice. 
 
Duration         : 30 days 
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CONDUCT OF THE STUDY: 
 
A number of 20 patients who satisfied the inclusion and exclusion criteria were 
admitted to the clinical trial. Patients informed consent was obtained. Routine   
haematological ,urine  investigations along with U.S.G/KUB  abdomen were assessed 
before and after  treatment. Trial drug  was issued to out  patients  once in 7 days for 30 
days .Each  time they were assessed clinically. For in- patients the trial drug were issued 
daily and they were monitored every day. Dietary advice was given. Haematological 
,urine investigations and U.S.G abdomen were taken before and after treatment. Patients 
was informed to report about adverse effects if any. 
Among 20 patients 11 patients are male 9 patients are female.  
(trial drug 2 table 20,chart 1). 
 
Among 20 patients , 
4 patients are in the age group of 20-30years.  
11 patients are in the age group of 30-45years.  
5 patients are in the age group of 45-60  years.( trial drug 2 table 20,bar  
diagram 5). 
 
CLINICAL SYMPTOMS: 
 
Among  20 patients  included in clinical trial , 16 patients had loin pain radiating 
to groin,11 patients showed frequency of  micturition  and  dysuria , 19 patients had  
burning micturition , 16 and 14 patients had  nausea and vomiting  respectively,6 patients 
had fever. 3 patients  had oliguria. (trial drug 2 table 22) 
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PROGNOSIS : 
 
During the  treatment with Sarva Noi Linga Chenduram  for the  patients included 
in  clinical trial  80% showed decrease in loin pain radiating to groin ,80% showed 
decrease in frequency of micturition and dysuria ,1% didn’t  show response for 
oliguria,70% showed decrease in burning micturition ,10%  didn’t  show  response  for 
haematuria, 75% and 70%  showed  decrease in nausea and vomiting respectively.( trial 
drug 2 bar diagram 6 ,table 21).  
 
There was  a significant reduction in the size of renal calculi as per the  U.S.G  
abdomen report after the treatment. (trial drug 2 ,table 22) 
 
Symptoms were reduced which is statistically significant. ( trial drug 2 table 23). 
 
Reduction in the size of the calculi which is statistically significant.( trial drug 2 
table 24) 
 
Stones were expelled in 15 % of cases. Stone analysis was carried out .It reveals 
the   presence of   calcium, phosphrous  and oxalate .(annexure 2). 
 
No adverse reactions were estsblished during the study period. 
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                                                      DISCUSSION 
The principle aim of this study was to assess the pre-clinical safety and efficacy 
and to evaluate the therapeutic efficacy of the drug Sarva Noi Linga Chenduram   in the 
management of Kalladaippu (Renal calculi). 
The literary evidence from the  siddha text  and modern science reviews  supports 
the  Lithontriptic   activity of the drug.  
Biochemical analysis: 
The biochemical analysis of the drug reveals the presence of  sulphate, borate. 
AAS studies   presented  quantity of mercury and borate in “Sarva  Noi Linga 
Chenduram”    which are within normal limits. 
Toxicological studies: 
In acute toxicity study, the animals treated with “Sarva  Noi Linga Chenduram”  
1000mg/kg were showed tolerance with negligible toxic signs. Hence the one tenth of the 
dose was selected as median therapeutic dose for the further study. 
Toxic effect was observed at 200mg/kg of Sarva Noi Linga Chenduram treated via 
oral route over a period of 28 days. So, it can be concluded that the Sarva Noi Linga 
Chenduram can be prescribed for therapeutic use in human with the dosage 
recommendations of upto maximum of 100mg/kg body weight p.o. for long term 
administrations the 20-30% of dose reduction is very essential to avoid organ damage. 
Pharmacological studies: 
Following ethylene glycol administration the excretion of calcium, oxalate, 
phosphate and protein were found to be increased in lithiatic group while in standard, test 
groups these levels were significantly decreased (P<0.01).  
All the observations enabled us to confirm the inhibitory potential of Sarva Noi 
Linga Chenduram on ethylene glycol induced lithiasis. 
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The presented data indicate that administration of  Sarva Noi Linga Chenduram to 
rats with ethylene glycol induced lithiasis reduced the formation of urinary stones, 
regarding lithontriptic activity of the drug “ Sarva Noi Linga Chenduram” 
 
The mechanism underlying this effect is still unknown, but is apparently related to 
diuresis and lowering of urinary concentrations of stone forming constituents. These 
effects could conclude the Lithontriptic property of Sarva Noi Linga Chenduram. 
Clinical observation: 
Clinical symptoms: 
      Among  20 patients  included  in clinical trial , 16 patients had loin pain radiating 
to groin,11 patients showed  frequency of  micturition  and  dysuria , 19 patients had  
burning micturition , 16 and 14 patients showed nausea and vomiting  respectively,6 
patients had fever. 3 patients showed oliguria. 
 
Prognosis in symptoms: 
  Among the patients integrated in clinical trial  80% showed decrease in pain ,80% 
showed decrease in frequency of micturition and dysuria ,1% didn’t  show response for 
oliguria,70% showed decrease in burning micturition,10%  didn’t  show  response  for 
haematuria, 75% and 70% showed  decrease in nausea and vomiting respectively. 
Although the drug produced some  toxicity for higher dosage  in animal model 
there were no toxic symptoms, adverse effects ,altered  haematological investigations for 
the recommended dosage in clinical trial.  
Bio-statistics: 
In prognosis of symptoms Statistical analysis-paired ‘t’ test “P”  value showed 
0.240 which is moderately significant and for size of renal calculi it showed  0.001 which 
is highly significant.   
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Siddha Aspect : 
"¿¢Äò¾¢ ¦ÄØó¾ À¢½¢¿£í¸¡ì ¸¢Ãó¾¢ 
ºÄòÐ¼§É Ý¨Ä¦ÅÊ¾¡É¸üÚõ-ÀÄò¾¾¡õ 
º¡¾¢Ä¢í¸ò ¾¢ýÌ½ò¨¾î º¡üÈ¢§Éý ºýÉ¢Ó¾ø 
µÐÍÃõ §À¡§Á ´ ¢óÐ." 
¿¢Äò¦¾Øó¾ À¢½¢-À¢Õ¾¢Å¢ â¾ ¯ÚôÒ¸ ¢ø ¯ñ¼¡õ §¿¡ö¸û;ºÄôÀ¢½¢-
«ôÒ â¾ ¯ÚôÒ¸ ¢ø ¯ñ¼¡Ìõ §¿¡ö¸û. 
It is mentioned in the siddha text   “«ôÒ â¾ ¯ÚôÒ¸ ¢ø ¯ñ¼¡Ìõ 
§¿¡ö¸¨  ¿£ìÌõ” for Lingam that means diseases related with fluids  and also 
Venkaram has lithontriptic,diuretic activity. 
According to AAS studies the the quantity of mercury in Sarva noi linga 
chenduram is 0.0146 ppm which is within normal range .Limit for mercury in  drugs is 1 
ppm.31.  So the drug might not have been produced toxic effects during the treatment 
period.  
As per the previous studies,   mercurial compounds possess diuretic activity which 
supports lithontriptic activity of the drug. 
An important reason for acute and chronic renal failure, includes both 
nephrolithiasis and urolithiasis. Medical management of lithiasis, today, includes 
lithotripsy and surgical procedures. Unfortunately, the underlying risk factors are not 
corrected by these techniques; hence there is a need to continue the medical supervision 
and therapy to prevent stone recurrence. The recurrence of urolithiasis represents a 
serious problem as patients who have formed one stone are more likely to form another. 
Not all standard pharmaceutical drugs used to cure urolithiasis are effective in all patients, 
and many have adverse effects that compromise their long-term use.  
 
Hence Sarva Noi linga Chenduram can be a better choice of drug in the 
management of Kalladaippu(Renal calculi).  
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SUMMARY 
 The literary evidence strongly supports the  Lithontriptic  activity of  “Sarva  noi 
linga chenduram”. 
 The drug “Sarva  Noi Linga Chenduram” had  been  selected for this study to 
evaluate its Lithontriptic   activity in the management  of  Kalladaippu (Renal 
calculi). 
 Biochemical analysis of   “Sarva  Noi Linga Chenduram”  drug  reveals the 
presence of sulphate, borate. 
 AAS  studies  presented  quantity of mercury and borate in “Sarva  Noi Linga 
Chenduram”    which were  within normal limits. 
 In acute toxicity study, the animals treated with 1000mg/kg were showed 
tolerance with negligible toxic signs. 
 In sub acute toxicity study  toxic effect was observed at 200mg/kg of “Sarva  Noi 
Linga Chenduram”    treated via oral route over a period of 28 days. So, it can be 
concluded that the Sarva Noi Linga Chenduram can be prescribed for therapeutic 
use in human with the dosage recommendations of upto maximum of 100mg/kg 
body weight p.o. for long term administrations the 20-30% of dose reduction is 
very essential to avoid organ damage. 
  Administration of  Sarva Noi Linga Chenduram to rats with ethylene glycol 
induced urolithiasis reduced the formation of urinary stones. 
 A number of 20 patients were recruited in clinical trial  satisfying the inclusion 
criteria.  
The drug Sarva  Noi Linga Chenduram was issued  to the patients once in 7 days 
for 30 days. 
 On account of  clinical trial after treament   with  “Sarva  Noi Linga Chenduram”     
80%  of patients showed decrease in pain ,80% showed decrease in frequency of 
micturition and dysuria, 1% didn’t  show response for oliguria,70% showed 
decrease in burning micturition ,10%  didn’t  show  response  for haematuria, 75% 
and 70% showed  decrease in nausea and vomiting respectively. 
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 There was a significant reduction in the size of renal calculi as per the U.S.G  
abdomen report after the treatment .Stones were  expelled in 15 % of cases. Stone 
analysis was carried out .It reveals the presence of  calcium, phosphrous and 
oxalate. 
 In prognosis of symptoms Statistical analysis-paired ‘t’ test “P”  value showed 
0.240 which is moderately significant and for size of renal calculi it showed  0.001 
which is highly significant 
 So the drug  “Sarva  Noi Linga Chenduram”   is  considered to be statistically 
significant in the management of  kalladaippu. 
 The drug “Sarva  Noi Linga Chenduram”   has 
lithontriptic  Activity. 
Encouraging clinical results. 
 From the clinical  trial and statistical analysis it substantiates  that the drug “Sarva  
Noi Linga Chenduram”    is statistically significant on lithontriptic   activity in the 
management of  Kalladaippu (Renal calculi) in upcoming days. 
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CONCLUSION 
 The literature and research journal review of the drug Sarva Noi linga Chenduram  
supports  that it has lithontriptic activity. 
 The safety studies (acute toxicity and repeated oral toxicity) studies conducted 
revealed that the trial drug Sarva Noi linga Chenduram  is safe. Hence it can be 
reasonably assumed that the drug is safe for human use. 
 The pharmacological study conducted in animal model showed significant 
Lithontriptic  activity. 
 Clinical study revealed the therapeutic efficacy of the trial drug by showing, 
reduction in symptoms and size of renal calculi significantly. There were no 
adverse reactions complained during the clinical trial. 
 Hence, the drug Sarva Noi linga Chenduram  can be used in the management of  
Kalladaippu(Renal calculi) 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
TABLE -1   DRUG -1 AMUKKARA KIZHANGU  CHOORANAM 
QUALITATIVE ANALYSIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE -1 PHYSICAL PROPERTIES 
S.NO CHARECTRISTIC TESTS RESULTS 
1 Ph 5.58 
2 TOTAL ASH 0.33 
3 WATER SOLUBLE ASH 0.01 
4 ACID INSOLUBLE ASH 0.05 
 
  
 
 
 
S.NO PARAMETERS RESULTS 
1 Phosphate Absent 
2 Sulphate absent 
3 Magnesium absent 
4 Iron absent 
5 Amino acids present 
6 Starch absent 
7 Flavanoids absent 
8 Proteins  absent 
9 Tannins  absent 
10 Glycosides  present 
TABLE – 3 PREMILINARY ACID,BASIC RADICALS PHYTOCHEMICAL   
SCREENING 
 
S.NO CONSTITUENTS AKC 
1 Magnesium Absent  
2 Iron(ferric) Absent 
3 Iron (ferrous) Present  
4 Sulphate  Absent 
5 Sodium Absent 
6 Starch  Absent 
7 Sulphate Absent 
8 Phosphate  Absent 
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489 nm 3D display graph 7 
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 Derivatisation 10µl (498nm) graph  9 
TOXICITY STUDIES 
                  TABLE- 4 
Table 4: Dose finding experiment and its behavioral Signs of Toxicity 
No Dose mg/kg 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. 1000 + - - + - + - - - - - - - - - - - - - - 
2 2000 + - - + - + - - - - - - - - - - - - - - 
3 5000 + - - + - + + + - - - - - - - - - - +  - 
 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. Decreased Motor 
Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 
15.Lacrimation 16. Exophthalmos 17. Diarrhoea 18. Writhing 19. Respiration 20. Mortality 
 
Table 5. Body wt (g) of rats exposed to Amukkara Kizhangu Chooranam for 28days. 
Dose 
(mg/kg/day) 
Days 
1 7 14 21 28 
Control 114.215.12 118.976.15 121.255.46 126.486.18 128.045.49 
100 118.354.22 123.105.11 123.145.82 125.526.02 126.446.00 
200 117.185.10 119.056.45 122.005.43 124.126.10 126.307.02 
400 115.105.24 118.025.88 120.106.33 121.786.41 125.146.37 
Values are mean  S.E.M. (Dunnet ’t' test). nsP>0.05. Vs. Control group N=6. 
 
 
 
 
Table 6. Food (g/day) intake of rats exposed to Amukkara Kizhangu Chooranam for 
28days. 
Dose 
(mg/kg/day) 
Days (gms/rats) 
1 7 14 21 28 
Control 42.002.54 42.162.10 45.192.10 48.152.50 49.123.10 
100 42.222.65 44.102.12 46.442.26 45.152.62 46.183.08 
200 41.312.30 42.112.18 45.602.28 45.682.18 46.043.04 
400 42.102.62 42.282.35 46.112.52 45.312.06 45.282.88 
Values are mean  S.E.M. (Dunnet ’t' test). nsP>0.05. Vs. Control group N=6. 
 
Table 7. Water (ml/day) intake of rats exposed to Amukkara Kizhangu Chooranam 
for 28days. 
 
Dose 
(mg/kg/day) 
Days(ml/rat) 
1 7 14 21 28 
Control 50.122.92 52.113.35 54.223.10 52.353.13 51.223.90 
100 52.102.40 50.123.08 55.264.46 46.163.08 48.452.98 
200 49.042.28 40.183.85 48.803.37 44.172.88 49.453.28 
400 51.143.46 54.973.00 50.223.81 49.523.17 50.823.45 
Values are mean  S.E.M. (Dunnet ’t' test). nsP>0.05. Vs. Control group N=6. 
 
 
Table 8. Hematological parameters after 28days treatment with Amukkara Kizhangu 
Chooranam in rats. 
Parameter Control 100 mg/kg 200 mg/kg 400 mg/kg 
Red blood cell 
(mm3) 
5.060.51 4.980.48 5.150.49 5.080.50 
HB (%) 14.100.34 15.150.30 14.500.47 15.020.44 
Leukocyte 
(x103/Cu.mm) 
8.221.9 8.250.89 8.071.15 8.431.34 
Platelets(K/µl) 44823.10 49632.24 48732.20 49530.46 
MCV (gl) 55.484.80 52.124.28 55.004.20 54.104.16 
N 15.451.38 15.201.17 41.800.86** 15.153.19 
L 85.102.40 80.803.41 83.283.52 85.123.48 
M 1.400.33 1.400.38 1.400.28 1.400.26 
E 1.000.00 1.000.22 1.000.11 1.000.11 
B 00.00 00.00 00.00 00.00 
ESR(mm) 100 100 100 100 
PCV 45.302.68 45.202.48 45.173.02 45.403.00 
Values are mean  S.E.M. (Dunnet ’t' test). **P<0.01. Vs. Control group N=6. 
 
 
 
 
 
 
 
Table 9. Effect of treatment with Amukkara Kizhangu Chooranam biochemical 
parameters. 
LFT 
Dose (mg/kg) Control 100 mg/kg 200 mg/kg 400 mg/kg 
Total Bilirubin (mg/dL) 0.290.05 0.260.06 0.280.05 0.250.04 
Bilirubin direct (mg/dL) 0.210.07 0.220.09 0.190.05 0.210.06 
ALP (U/L) 102.1410.17 104.1411.02 116.3010.10 114.210.32 
SGOT (U/L) 116.206.10 115.176.50 110.855.98 116.046.78 
SGPT(U/L) 36.042.04 34.813.00 35.082.15 36.602.17 
Total Protein(g/dl) 6.021.30 6.100.10 7.500.25 8.120.40 
Albumin(g/dl) 2.210.25 2.190.24 3.460.23** 3.120.11* 
Globulin(g/dl) 4.020.17 5.120.20** 4.280.20 4.810.28* 
Values are mean of 6 animals  S.D 
                            E.M. *P<0.05; **P<0.01. Vs. Control group N=6. 
Table-10 RFT 
Dose (mg/kg) Control 100 mg/kg 200 mg/kg 400 mg/kg 
Urea(mg/dL) 5.421.68 4.302.16 5.42.04 5.811.32 
Creatinine (mg/dL) 0.710.05 0.700.05 0.720.06 0.710.05 
Uric acid (mg/dL) 3.610.14 4.100.18 4.160.16 4.060.14 
Na m.mol 112.785.26 114.25.00 118.125.22 114.105.00 
K m.mol 5.202.80 5.451.16 5.01.06 6.152.00 
Cl m.mol 100.014.14 101.085.11 99.464.24 101.415.21 
Values are mean  S.E.M. nsP>0.05. Vs. Control group N=6. 
 
 
 
 
 
Table-11. Lipid Profile 
Dose (mg/kg) Control 100 mg/kg 200 mg/kg 400 mg/kg 
Total cholestrol(mg/dL) 78.682.57 71.102.42 70.523.28 72.503.04 
HDL(mg/dL) 123.022.74 113.252.78 124.003.45 123.202.44 
LDL(mg/dL) 42.002.35 41.523.01 40.313.10 42.243.22 
VLDL(mg/dl) 26.382.22 25.802.41 26.042.64 25.012.28 
Triglycerides (mg/dl) 28.243.02 25.162.42 26.233.54 28.102.71 
Blood glucose(mg/dl) 85.154.82 91.104.05 93.135.00 94.112.45 
 
Values are mean  S.E.M. nsP>0.05. Vs. Control group N=6. 
Table-12 Urine Analysis 
Parameters Control 100 mg/kg 200 mg/kg 400 mg/kg 
Colour Yellow Yellow Yellow Yellow 
Transparency Clear Slightly turbid Slightly cloudy Slightly turbid 
Specific gravity 1.010 1.010 1.010 1.010 
PH >7.2 >8.0 >7.5 >7.5 
Protein Nil 1+ 1+ 2+ 
Glucose Nil Nil Nil Trace 
Bilirubin -ve -ve -ve -ve 
Ketones -ve -ve -ve -ve 
Blood Absent Absent Absent Absent 
Urobilinogen Normal Normal Normal Normal 
Pus cells 0-cells/HPF 1-cell/HPF 2-cells/HPF 1-cell/HPF 
RBCs Nil Nil 0-1cells/HPF Nil 
Epithelial cells Nil 1-cell/HPF Nil 1-cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
Others Bacteria seen Bacteria seen Bacteria seen Bacteria seen 
 
 
Table 13. Effect of oral administration of Amukkara Kizhangu Chooranam on organ 
weight 
Dose (mg/kg) Control 100 mg/kg 200 mg/kg 400 mg/kg 
Liver (g) 3.100.10 3.140.15 3.150.12 3.050.17 
Heart (g) 0.320.04 0.320.05 0.350.04 0.350.04 
Lung (g) 0.490.16 0.440.14 0.380.12 0.420.11 
Spleen (g) 0.450.05 0.480.04 0.460.04 0.450.05 
Ovary (g) 1.200.18 1.420.15 1.280.15 1.260.14 
Testes (g) 2.180.14 2.450.22 2.400.25 2.410.21 
Brain (g) 2.060.15 2.080.13 0.060.14** 2.030.14 
Kidney (g) 0.830.04 0.810.04 0.800.04 0.820.05 
Stomach (g) 1.160.12 1.240.10 1.180.11 1.150.12 
Values are mean of 6 animals  S.E.M. (Dunnet ’t' test). **P<0.01 Vs. Control group N=6. 
 
 
PHARMACOLOGICAL  STUDIES 
 Table 14: Effect of Amukkara Kizhangu Chooranam on body weight of 
Cholesterol rich diet induced hyperlipidemic rats 
Groups Body Weight (gm.) 
Initial 1st Week 2nd Week 3rd Week 4th Week 
Normal control 154.28±2.73 156.18±2.35 158.12±2.44 161.22±2.92 163.46±3.00 
Hyperlipidemic 
Control 
156.24±2.54 156.99±2.71 178.22±2.60**,a 196.84±2.48**,a 236.13±2.75**,a 
AKC 100mg/kg 153.88±2.00 157.04±2.36 166.79±2.48b 182.40±3.22**,a 180.11±2.44**,a 
AKC 200mg/kg 156.62±2.26 159.00±2.44 166.15±2.56b 180.12±2.82**,a 186.18±2.52**,a 
Lovastatin 155.18±2.11 158.27±2.68 165.92±2.88a 179.37±2.46**,a 180.40±2.11**,a 
 
Values are as mean ± SEM (n=6)  
Values are statistically significant at *P<0.05, **P<0.01, ***P<0.001  
Comparison made between Group II Vs Group I  
aP<0.001, bP<0.01, cP<0.05 compared between Group III, IV, V Vs Group II. 
 
Table 15: Effect of Amukkara Kizhangu Chooranam on Lipid profiles of Cholesterol 
rich diet induced hyperlipidemic rats  
Groups Cholesterol 
(mg/dl) 
Triglycerides 
(mg/dl) 
HDL 
(mg/dl) 
LDL 
(mg/dl) 
VLDL 
(mg/dg) 
Normal control 122.15±4.96 110.34±4.88 55.46±2.46 48.18±4.10 23.85±2.83 
Hyperlipidemic 
Control 
179.46±5.13**,a 285.17±4.10**,a 42.18±2.30**,a 87.34±4.15**,a 62.10±3.06**,a 
AKC 100mg/kg 142.00±4.37*,a 159.33±4.48**,a 68.10±3.24*,a 41.64±3.00a 25.14±3.44a 
AKC 200mg/kg 138.81±3.48*,a 147.10±3.52**,a 44.65±2.88* 70.15±3.64**,b 37.33±3.10*,a 
Lovastatin 126.77±2.87a 138.98±3.12**,a 58.79±3.00a 44.52±3.74a 31.64±2.46a 
 
Values are as mean ± SEM (n=6)  
Values are statistically significant at *P<0.05, **P<0.01, ***P<0.001  
Comparison made between Group II Vs Group I  
aP<0.001, bP<0.01, cP<0.05 compared between Group III, IV, V Vs Group II. 
 
  Table 16: Effect of Amukkara Kizhangu Chooranam on atherogenic index and 
percentage protection of different groups. 
Groups Atherogenic Index(AI) % Protection 
Normal control 2.38±0.16 --- 
Hyperlipidemic Control 4.65±0.22** --- 
AKC 100mg/kg 3.11±0.04**,a 33.11 
AKC 200mg/kg 3.48±0.04**,a 25.16 
Lovastatin 2.86±0.06**,a 38.49 
 
 
 
Table 17: Effect of Amukkara Kizhangu Chooranam on SGOT, SGPT Total protein, 
Urea and Blood glucose levels of Cholesterol rich diet induced hyperlipidemic  
rats on day 28. 
Groups SGOT(U/I) SGPT(U/I) Total 
Protein 
(gm/dl) 
Urea 
(mg/dl) 
Blood 
Glucose 
(mg/dl) 
Normal control 166.21±4.80 61.16±2.72 5.99±0.32 42.04±0.92 84.87±1.52 
Hyperlipidemic 
Control 
234.48±5.50**,a 130.40±4.56**,a 7.22±0.30**,a 26.11±0.98**,a 92.56±1.88**,a 
AKC 100mg/kg 159.87±5.75a 64.11±2.31a 6.10±0.30a 34.08±2.10**,a 85.13±1.32a 
AKC 200mg/kg 198.40±5.44**,a 101.02±2.64**,a 6.98±0.28** 40.64±2.45a 83.10±1.14a 
Lovastatin 172.15±5.62a 72.46±2.87**,a 6.23±0.31a 36.98±2.00**,a 82.36±1.18*,a 
 
Values are as mean ± SEM (n=6)  
Values are statistically significant at *P<0.05, **P<0.01, ***P<0.001  
Comparison made between Group II Vs Group I  
aP<0.001, bP<0.01, cP<0.05 compared between Group III, IV, V Vs Group II  
 
 
Table 18: Effect of Amukkara Kizhangu Chooranam on vital organ weights of 
Cholesterol rich diet induced hyperlipidemic rats on day 28. 
Groups Liver(gm) Heart(gm) Kidney(gm) 
Normal control 5.45±0.28 0.61±0.05 0.55±0.18 
Hyperlipidemic 
Control 
7.88±0.17**,a 1.02±0.05**,a 0.84±0.03**,a 
AKC 100mg/kg 5.82±0.15*,a 0.58±0.10a 0.58±0.02a 
AKC 200mg/kg 6.61±0.3**,a 0.64±0.02a 0.64±0.03a 
Lovastatin 5.92±0.03**,a 0.62±0.02a 0.60±0.14a 
 
Values are as mean ± SEM (n=6)  
Values are statistically significant at *P<0.05, **P<0.01, ***P<0.001  
Comparison made between Group II Vs Group I  
aP<0.001, bP<0.01, cP<0.05 compared between Group III, IV, V Vs Group II. 
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Table 19 
                                     CLINICAL STUDIES 
                                            AGE WISE DISTRIB UTION FOR TRIAL DRUG 1 
 
 
 
 
 
 
 
                                             
 
 Table 20  GENDER  WISE DISTRIBUTION FOR TRIAL DRUG 1 
 
S.NO GENDER NO OF PATIENTS PERCENTAGE 
1 MALE 9 45% 
2 FEMALE 11 55% 
  
 
                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO AGE NO OF 
PATIENTS 
PERCENTAGE 
1 30-45 8 40% 
2 45-60 12 60% 
 
            AGE WISE DISTRIBUTION FOR TRIAL DRUG 1 
 
 
 
 
 
Bar diagram 8 
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Statistical Analysis:  TRIAL DRUG 1 table 22 
All collected data were entered into MS Excel software using different columns as 
variables and rows as patients. SPSS software was used to perform statistical analysis. 
Basic descriptive statistics include frequency distributions and cross-tabulations were 
performed. The quantity variables were expressed as Mean ± Standard Deviation and 
qualitative data as percentage. A probability value of <0.05 was considered to indicate as 
statistical significance. Paired ‘t’ test was performed for determining the significance 
between before and after treatment. 
S.NO Obs variable Mean Std. 
Deviation 
t.  value p value 
1 20 BT  
S.CHO 
245.10 50.004 4.156 .001 
AT 
S.CHO 
208.75 30.375 
2 20 BTHDL 39.05 5.726 -1.650 .115 
ATHDL 40.95 5.916 
3  20 BTLDL 129.80 28.050 2.722 .014 
ATLDL 112.35 30.432 
4 20 BTVLDL 50.90 15.650 2.244 .037 
ATVLDL 45.65 16.429 
5 20 BTTGL 268.85 60.796 3.624 .002 
ATTGL 224.40 74.826 
 
‘p’ value for S.T.CHOLESTEROL is 0.001 .TGL is 0.002 which is statistically significant. 
 
 
 
 
 
 
 
 
 
SARVA NOI LINGACHENDURAM TRIAL DRUG 2 
Table 1 QUALITATIVE ANALYSIS 
 
                                     
S.NO PARAMETERS RESULTS 
1 Sodium Absent  
2 Phosphate Absent 
3 Magnesium Absent 
4 Sulphate Present  
5 Iron Absent 
6 Chloride Absent 
7 Calcium Absent 
8 Borate  Absent 
 
 
 
 
                      QUANTITATIVE ANALYSIS  TRIAL DRUG 2 TABLE 2 
 
 
S.NO PARAMETERS RESULTS METHOD 
1 Mercury  0.146 AAS 
2 Sulphur ND AAS 
3 Borate  2.26 AAS 
 
 
 
 
 
 
 
 
PHYSICAL PROPERTIES TRIAL DRUG 2  TABLE 3 
 
 
S.NO CHARECTRISTIC TESTS RESULTS 
1 Ph 9.05 
2 TOTAL ASH 0.41 
3 WATER SOLUBLE ASH 0.35 
4 ACID INSOLUBLE ASH 0.29 
 
 
 
TABLE 4 
 
PRELIMINARY ACID BASIC RADICALS  SCREEENING TRIAL DRUG 2 
 
 
S.NO CONSTITUENTS SNLC 
1 Magnesium Absent 
2 Iron(ferric) Absent 
3 Iron (ferrous) Absent 
4 Sulphate  Present  
5 Sodium Absent 
6 Starch  Absent 
7 Sulphate Absent 
8 Phosphate  Absent 
                                                           
 
 
 
 
 
 
 
 
 
 
TOXICITY STUDIES 
 
TRIAL DRUG 2 
Table 5: Dose finding experiment and its behavioral Signs of Toxicity 
No Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. 500 + - - + - + - - - - - - - + - - - - + - 
2 1000 + + - + + + - + + + - - - + - - - + + - 
3 2000 + + - + + + - + + + - - - + + + - + + - 
 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. Decreased 
Motor Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 11. Catatonia 12. Muscle relaxant 13. 
Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. Diarrhoea 18. Writhing 19. Respiration 20. 
Mortality 
 
Table 6. Body wt (g) of rats exposed to Sarva Noi Linga Chendooram for 28days. 
Dose 
(mg/kg/day) 
Days 
1 7 14 21 28 
Control 110.524.85 114.215.46 118.105.05 121.185.12 126.314.84 
50 118.254.45 112.105.12 101.125.12 100.024.22* 108.205.01 
100 115.335.14 110.225.00 104.025.13 108.174.22 110.105.11 
200 116.465.28 109.104.72 110.125.00 110.485.10 110.104.10 
Values are mean  S.E.M. (Dunnet ’t' test). *P>0.05; N=6. 
Table 7. Food (g/day) intake of rats exposed to Sarva Noi Linga Chendooram for 
28days. 
Dose 
(mg/kg/day) 
Days (gms/rats) 
1 7 14 21 28 
Control 40.002.25 43.162.12 45.102.46 44.642.58 45.152.15 
50 45.302.41 44.102.18 44.202.30 45.142.29 46.004.02 
100 43.352.10 45.422.63 45.152.34 44.252.18 45.143.00 
200 44.152.22 45.242.55 45.342.52 45.432.60 45.402.48 
Values are mean  S.E.M. (Dunnet ’t' test). nsP>0.05. N= 
 
Table 8. Water (ml/day) intake of rats exposed to Sarva Noi Linga Chendooram for 
28days. 
 
Dose 
(mg/kg/day) 
Days(ml/rat) 
1 7 14 21 28 
Control 48.102.45 50.183.30 52.483.14 52.043.13 51.463.81 
50 50.122.42 50.423.12 51.124.10 50.003.52 49.422.42 
100 49.002.20 44.483.01 46.673.28 48.022.48 49.403.20 
200 50.002.18 50.232.04 50.153.10 51.322.74 50.173.00 
Values are mean  S.E.M. (Dunnet ’t' test). nsP>0.05. N=6. 
 
Table 9. Hematological parameters after 28days treatment with Sarva Noi Linga 
Chendooram. 
Parameter Control 50 mg/kg 100 mg/kg 200 mg/kg 
Red blood cell 
(mm3) 
5.210.44 5.260.32 5.180.40 5.120.41 
HB (%) 14.650.38 15.120.40 15.520.45 16.000.32 
Leukocyte 
(x103/Cu.mm) 
8.721.1 8.580.34 8.401.00 8.321.12 
Platelets(K/µl) 44825.00 45630.41 47622.14 48123.04 
MCV (gl) 52.214.26 51.344.26 52.104.71 53.124.20 
N 15.141.42 15.421.19 14.220.50 14.871.14 
L 84.122.54 83.922.48 82.002.75 83.212.92 
M 1.500.38 1.420.40 1.410.32 1.420.36 
E 1.010.10 1.000.21 1.000.18 1.000.14 
B 00.00 00.00 00.00 00.00 
ESR(mm) 100 100 100 100 
PCV 46.302.45 46.422.81 45.753.00 45.662.38 
 
Values are mean  S.E.M. (Dunnet ‘t' test). *P<0.05; **P<0.01. N=6. 
 
Table 10. Effect of treatment with Sarva Noi Linga Chendooram on biochemical 
parameters. 
 
Dose (mg/kg) Control 50 mg/kg 100 mg/kg 200 mg/kg 
Total Bilirubin 
(mg/dL) 
0.280.04 0.280.04 0.270.05 0.280.05 
Bilirubin direct 
(mg/dL) 
0.200.05 0.240.04 0.220.05 0.230.05 
ALP (U/L) 102.1010.00 104.429.20 110.1810.05 112.3210.27 
SGOT (U/L) 114.054.14 112.104.00 110.424.44 112.105.85 
SGPT(U/L) 34.102.66 35.143.15 35.042.18 35.622.14 
Total Protein(g/dl) 6.341.42 6.700.14 7.110.29 7.100.27 
Albumin(g/dl) 2.410.28 2.710.25 2.820.38 2.900.22 
Globulin(g/dl) 4.180.20 5.300.24** 4.770.24 4.700.24 
Values are mean  S.E.M. (Dunnet ’t' test). **P<0.01 Vs control group N=6. 
 
 
 
 
 
 
Table-11 RFT 
Dose (mg/kg) Control 50 mg/kg 100 mg/kg 200 mg/kg 
Urea (mg/dL) 4.561.88 5.441.25 5.781.22 5.741.70 
Creatinine 
(mg/dL) 
0.730.04 0.720.04 0.730.05 0.820.04 
Uric acid (mg/dL) 3.520.15 4.120.18* 4.100.18 4.210.14* 
Na m.mol 115.465.04 115.515.10 115.104.22 114.104.10 
K m.mol 5.252.46 5.451.67 5.441.50 4.802.31 
Cl m.mol 102.244.30 101.004.45 98.444.24 100.774.04 
Values are mean  S.E.M. (Dunnet ‘t' test). *P<0.05; Vs control group N=6. 
 
Table-12. Lipid Profile 
Dose (mg/kg) Control 50 mg/kg 100 mg/kg 200 mg/kg 
Total cholestrol(mg/dL) 80.112.80 79.142.37 78.783.02 76.992.90 
HDL(mg/dL) 123.252.50 122.202.27 123.103.00 121.252.24 
LDL(mg/dL) 42.122.55 42.242.80 43.002.88 42.622.04 
VLDL(mg/dl) 26.102.40 27.382.14 26.102.48 25.402.25 
Triglycerides (mg/dl) 27.242.62 26.282.28 27.203.00 28.082.55 
Blood glucose (mg/dl) 92.404.50 94.243.15 94.223.00 95.282.42 
Values are mean  S.E.M. (Dunnet ’t' test). nsP>0.05. Vs control group N=6. 
Table-13 Urine Analysis 
Parameters Control 50 mg/kg 100 mg/kg 200 mg/kg 
Colour Yellow Reddish 
Yellow 
Reddish 
Brown 
Reddish Brown 
Transparency Clear Slightly turbid Turbid Turbid 
Specific gravity 1.010 1.010 1.010 1.010 
PH >7.2 >7.4 >7.2 >8.4 
Protein Nil 1+ 1+ 2+ 
Glucose Nil Nil Nil Trace 
Bilirubin -ve -ve -ve -ve 
Ketones -ve -ve -ve +ve 
Blood Absent Absent Absent Absent 
Urobilinogen Normal Normal Normal Normal 
Pus cells 0-cells/HPF 1-cell/HPF 2-cells/HPF 1-cell/HPF 
RBCs Nil Nil 0-1cells/HPF Nil 
Epithelial cells Nil 1-cell/HPF Nil 1-cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
Others Bacteria seen Bacteria seen Bacteria seen Bacteria seen 
 
 
 
 
 
 
 
 
 
Table 14. Effect of oral administration of Sarva Noi Linga Chendooram on organ 
weight 
Dose (mg/kg) Control 50 mg/kg 100 mg/kg 200 mg/kg 
Liver (g) 3.100.10 3.140.12 3.120.10 3.080.12 
Heart (g) 0.320.04 0.310.05 0.300.04 0.320.04 
Lung (g) 0.440.12 0.450.12 0.430.10 0.420.10 
Spleen (g) 0.450.05 0.460.05 0.460.05 0.460.05 
Ovary (g) 1.430.12 1.440.12 1.450.14 1.460.12 
Testes (g) 2.120.12 2.100.17 2.120.12 2.200.14 
Brain (g) 2.110.10 2.150.12 2.160.14 2.120.15 
Kidney (g) 0.800.05 0.780.05 0.810.05 0.820.05 
Stomach (g) 1.140.12 1.150.11 1.120.13 1.140.12 
Values are mean  S.E.M. (Dunnet ’t' test). nsP>0.05. Vs control group N=6. 
                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                  PHARMACOLOGICAL STUDIES 
 
Table 15: Diuretic activity of Sarva noi linga chendooram in rats 
 
Group Treatment 
and Dose 
Volume of 
Urine 
(ml/4hrs) 
Sodium 
(mMol/l) 
Potassium 
(mMol/l) 
Chloride 
(mMol/l) 
 
I Saline (10ml/ 
kg) 
0.86±0.17 79.8±7.5 61.0±5.5 95.6±9.0 
II SNLC (50 mg/ 
kg) 
0.94±0.15a 105.2±9.5 83.4±7.2 116.1±12.4 
III SNLC (100 
mg/ kg) 
1.35±0.14a 110.4±8.1 92.1±6.0* 128.6±7.8 
IV Frusemide (20 
mg/ kg) 
4.12±0.24 128.6±5.2 107.5±8.1 144.2±10.3 
 
All values are expressed as mean ±S.E.M for six rats in each group. 
Comparisons made between *p<0.05; T1,T2 Vs normal control.; ap<0.001 T1,T2 Vs 
Standard. 
 
Table 16: Estimation of Urinary Electrolytes of Normal and Urolithiatic Rats. 
S.No  Group & Drug 
Treatment 
Estimation of Urinary Electrolytes 
Oxalate(mg/dl) Calcium(mg/dl) Phosphate(mg/dl) 
1 Normal control 
(Saline) 
0.38±0.04 2.74±0.15 3.45±0.05 
2 Calculi 
induced(0.75% EG) 
2.13±0.06© 9.21±0.43© 8.16±0.10© 
3 Standard (Cystone 
750 mg/kg) 
1.22±0.07x 3.38±0.23x 3.92±0.07x 
4 T1 (SNLC 50 mg/kg) 0.751±0.23*** 5.79±0.10*** 5.11±0.09a,*** 
5 T2 (SNLC 100 mg/kg) 0.448±0.12b,*** 4.36±0.14a,*** 4.32±0.08c,*** 
All values are expressed as mean ±S.E.M for six rats in each group. 
Comparisons made between 
ap<0.001,bp<0.01,cp,<0.05; T1,T2 Vs Standard. 
***p<0.001,**p<0.01,*p<0.05 ; T1,T2 Vs Calculi induced. 
©p<0.001 , p<0.01,@p<0.05; Calculi induced Vs normal control. 
xp<0.001,yp<0.01,zp,<0.05; Calculi induced Vs Standard., One-way ANOVA followed by 
Tukey test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 17: Estimation of Kidney Homogenate Electrolytes of Normal And 
Urolithiatic Rats. 
S.No Group &Drug 
Treatment 
Estimation of Kidney Homogenate Parameters 
Oxalate(mg/dl) Calcium(mg/dl) Phosphate(mg/dl) 
1 Normal (Saline) 
 
0.186±0.03 3.431±0.28 
 
2.65±0.05 
 
2 Positive control (0.75% 
EG) 
 
1.742±0.09© 
 
6.024±0.20© 
 
4.10±0.14© 
 
3 Standard (Cystone 750 
mg/kg) 
 
0.446±0.05x 
 
4.326±0.19x 3.20±0.08x 
 
4 T1 (SNLC 50 mg/kg) 
 
0.689±0.05*** 
 
5.452±0.26c 
 
3.88±0.12a 
 
5 T2 (SNLC 100 mg/kg) 0.575±0.06*** 4.234±0.18*** 3.01±0.09*** 
All values are expressed as mean ±S.E.M for six rats in each group. 
Comparisons made between 
ap<0.001,bp<0.01,cp,<0.05; T1,T2Vs Standard. 
***p<0.001,**p<0.01,*p<0.05 ; T1,T2Vs Calculi induced. 
©p<0.001 , p<0.01,@p<0.05; Calculi induced Vs normal control. 
xp<0.001,yp<0.01,zp,<0.05; Calculi induced Vs Standard., One-way ANOVA followed by 
Tukey test. 
 
 
 
 
 
 
 
 
 
 
 
 Table 18: Estimation of Serum Parameters of Normal and Urolithiatic Rats. 
S.No Group & Drug Treatment 
Estimation of Serum Parameters 
BUN (mg/dl) Creatinine (mg/dl) 
Uric acid 
(mg/dl) 
1 Normal (Saline) 18.256±0.32 0.682±0.05 4.99±0.05 
2 Positive control (0.75% 
EG) 
27.109±0.36© 0.902±0.05@ 6.72±0.09© 
3 Standard (Cystone 750 
mg/kg) 
22.754±0.44x 0.918±0.04 5.56±0.07x 
4 T1 (SNLC 50 mg/kg) 34.022±0.65a,*** 1.226±0.05b,** 6.04±0.09b,*** 
5 T2 (SNLC 100 mg/kg) 30.239±0.48a,*** 1.101±0.07 6.12±0.08a,*** 
All values are expressed as mean ±S.E.M for six rats in each group. 
Comparisons made between 
ap<0.001,bp<0.01,cp,<0.05; T1,T2Vs Standard. 
***p<0.001,**p<0.01,*p<0.05 ; T1,T2Vs Calculi induced. 
©p<0.001 , p<0.01,@p<0.05; Calculi induced Vs normal control. 
xp<0.001,yp<0.01,zp,<0.05; Calculi induced Vs Standard., One-way ANOVA followed by 
Tukey test. 
 
 
 
 
 
 
 TRIAL DRUG 2 Bar diagram 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRIAL DRUG 2  Bar diagram 2 
     TRIAL DRUG 2  Bar diagram 3 
 
 
 
 
 
 
 
 
 
 
 
    
 
TRIAL DRUG 2  Bar diagram 4 
 
AGE WISE DISTRIBUTION TRIAL DRUG 2 
                                                         TABLE 19 
 
 
 
 
 
                                  GENDER WISE DISTRIBUTION   TRIAL DRUG 2 
                                                                 TABLE 20 
 
S.NO GENDER NO OF PATIENTS PERCENTAGE 
1 MALE 11 55% 
2 FEMALE 9 45% 
 
S.NO AGE WISE 
DISTRIBUTION 
NO OF 
PATIENTS 
1 20-30 4 
2 30-45 11 
3 45-60 5 
911
Gender
male
female
 
  
                             Bar diagram 5 TRIAL DRUG 2 
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 PROGNOSIS IN SYMPTOMS Of RENAL CALCULI TRIAL DRUG 2 
TABLE 21 
  No of patients  
S.NO SYMPTOMS BT AT (prognosis) 
1 Pain 16 13 
2 Frequency of 
micturition 
11 9 
3 Dysuria 11 9 
4 Oliguria 3 1 
5 Burning micturition 19 14 
6 Haematuria 6 4 
7 Nausea 16 15 
8 Vomiting 14 12 
9 Fever 6 6 
 
 S.NO OPD/IPD AGE SEX BTRTKCAL  
size in 
mm 
ATRKCAL 
size in 
mm 
BTLTKCAL 
size in 
mm 
ATLTKCAL 
size in 
mm 
1 C80114 36 F 2-3 0 2-3 4.5 
2 C79916 46 M 7 5 0 0 
3 C81077 51 F 6.6,2.9 1.16 4.2 3.7 
4 C81387 37 M 7 , 5 4,7,4,3.8 6 5 
5 C85062 36 M 0 0 4.3 3.2 
6 C86007 35 M 7 3 9 6 
7 C87501 45 F 5.3 3.3 5 4 
8 C79067 29 M 9,7.5. 7 10 9 
9 C89477 55 F 6 5 6 0 
10 C66643 25 M 0 0 9.9 6 
11 C89987 29 F 4,6 2,3 4,2 0 
12 C89500 27 F 5.3 5 4.2 4.2 
13 C21280 31 F 3.5 0 0 0 
14 C87193 35 F 0 5 4.2 0 
15 5017 45 M 0 0 6.1 0 
16 C77638 45 M 6 0 0 0 
17 C88424 38 M 10 0 9 6 
18 C79579 36 M 0 0 5,4 5,4 
19 C83911 35 F 10 6 0 0 
20 C89260 52 M 4.6 7 6 5 
 
                             SIZE OF RENAL CALCULI BEFORE AND AFTER TREATMENT TABLE 22 
 
                                BTRTKCAL –before treatment  right kidney calculus 
                                ATRKCAL- after treatment right kidney calculus 
                                BTLTKCAL-before treatment left kidney calculus 
                                ATLTKCAL-  After treatment left kidney calculus 
  
 
 
 
 
All collected data were entered into MS Excel software using different columns as 
variables and rows as patients. SPSS software was used to perform statistical analysis. 
Basic descriptive statistics include frequency distributions and cross-tabulations were 
performed. The quantity variables were expressed as Mean ± Standard Deviation and 
qualitative data as percentage. A probability value of <0.05 was considered to indicate as 
statistical significance. Paired ‘t’ test was performed for determining the significance 
between before and after treatment 
TRIAL DRUG 2 TABLE 23 
 
 
  
 
 
 
 
Trial drug 2 table 24 
 
 
 
 
 
 
Prognosis in symptoms of renal calculi  
variable Obs Mean  Std. 
Deviation 
t value P value 
sym BT 20 4.75 1.118 10.556 0.001 
AT 20 0.90 1.071 
Reduction in size of renal calculi  
variable Obs Mean  Std. 
Deviation 
t 
value 
P value 
size BT 20 10.930000 5.83610 4.856 <0.0001 
AT 20 6.488000 4.69628 
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